<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PIOGLITAZONE AND METFORMIN HYDROCHLORIDE- pioglitazone hydrochloride and metformin hydrochloride tablet, film coated </strong><br>Teva Pharmaceuticals USA Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use pioglitazone and metformin hydrochloride tablets USP safely and effectively.  See full prescribing information for pioglitazone and metformin hydrochloride tablets USP. <br>PIOGLITAZONE and METFORMIN hydrochloride tablets USP for oral use<br>Initial U.S. Approval: 2005</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span> AND <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span></span></h1>
<h1 class="Warning"><span class="Bold">See full prescribing information for complete boxed warning</span></h1>
<p class="Highlighta"><span class="Bold"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> </span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Thiazolidinediones, including pioglitazone, which is a component of pioglitazone and metformin hydrochloride tablets, cause or exacerbate <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> in some patients. (<a href="#i4i_section_id_8177ec74-2b3c-4e22-8fca-6355648bc970">5.1</a>) </span></dd>
<dt>•</dt>
<dd><span class="Bold">After initiation of pioglitazone and metformin hydrochloride tablets, and after dose increases, monitor patients carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (e.g., excessive, rapid <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and/or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>). If <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> develops, it should be managed according to current standards of care and discontinuation or dose reduction of pioglitazone and metformin hydrochloride tablets must be considered. (<a href="#i4i_section_id_8177ec74-2b3c-4e22-8fca-6355648bc970">5.1</a>) </span></dd>
<dt>•</dt>
<dd><span class="Bold">Pioglitazone and metformin hydrochloride tablets are not recommended in patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. </span></dd>
<dt>•</dt>
<dd><span class="Bold">Initiation of pioglitazone and metformin hydrochloride tablets in patients with established New York Heart Association (NYHA) Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is contraindicated. (<a href="#i4i_contraindications_id_6c47db78-3491-47bd-9c0c-26d9274bba72">4</a>, <a href="#i4i_section_id_8177ec74-2b3c-4e22-8fca-6355648bc970">5.1</a>) </span></dd>
</dl>
<p class="Highlighta"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span></span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> can occur due to metformin accumulation. The risk increases with conditions such as <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, excess alcohol intake, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. (<a href="#i4i_section_id_75c7c85e-1104-4b47-ac01-1d2707206413">5.2</a>) </span></dd>
<dt>•</dt>
<dd><span class="Bold">Symptoms include <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, increasing <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and nonspecific <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>. Laboratory abnormalities include low pH, increased <span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span>, and elevated blood lactate. (<a href="#i4i_section_id_75c7c85e-1104-4b47-ac01-1d2707206413">5.2</a>) </span></dd>
<dt>•</dt>
<dd><span class="Bold">If <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> is suspected, discontinue pioglitazone and metformin hydrochloride tablet and hospitalize the patient immediately. (<a href="#i4i_section_id_75c7c85e-1104-4b47-ac01-1d2707206413">5.2</a>)</span></dd>
</dl>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span> AND <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span></span></h1>
<h1 class="Warning"><span class="Bold">See full prescribing information for complete boxed warning</span></h1>
<p class="Highlighta"><span class="Bold"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> </span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Thiazolidinediones, including pioglitazone, which is a component of pioglitazone and metformin hydrochloride tablets, cause or exacerbate <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> in some patients. (<a href="#i4i_section_id_8177ec74-2b3c-4e22-8fca-6355648bc970">5.1</a>) </span></dd>
<dt>•</dt>
<dd><span class="Bold">After initiation of pioglitazone and metformin hydrochloride tablets, and after dose increases, monitor patients carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (e.g., excessive, rapid <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and/or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>). If <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> develops, it should be managed according to current standards of care and discontinuation or dose reduction of pioglitazone and metformin hydrochloride tablets must be considered. (<a href="#i4i_section_id_8177ec74-2b3c-4e22-8fca-6355648bc970">5.1</a>) </span></dd>
<dt>•</dt>
<dd><span class="Bold">Pioglitazone and metformin hydrochloride tablets are not recommended in patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. </span></dd>
<dt>•</dt>
<dd><span class="Bold">Initiation of pioglitazone and metformin hydrochloride tablets in patients with established New York Heart Association (NYHA) Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is contraindicated. (<a href="#i4i_contraindications_id_6c47db78-3491-47bd-9c0c-26d9274bba72">4</a>, <a href="#i4i_section_id_8177ec74-2b3c-4e22-8fca-6355648bc970">5.1</a>) </span></dd>
</dl>
<p class="Highlighta"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span></span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> can occur due to metformin accumulation. The risk increases with conditions such as <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, excess alcohol intake, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. (<a href="#i4i_section_id_75c7c85e-1104-4b47-ac01-1d2707206413">5.2</a>) </span></dd>
<dt>•</dt>
<dd><span class="Bold">Symptoms include <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, increasing <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and nonspecific <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>. Laboratory abnormalities include low pH, increased <span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span>, and elevated blood lactate. (<a href="#i4i_section_id_75c7c85e-1104-4b47-ac01-1d2707206413">5.2</a>) </span></dd>
<dt>•</dt>
<dd><span class="Bold">If <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> is suspected, discontinue pioglitazone and metformin hydrochloride tablet and hospitalize the patient immediately. (<a href="#i4i_section_id_75c7c85e-1104-4b47-ac01-1d2707206413">5.2</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Pioglitazone and metformin hydrochloride tablets USP are a thiazolidinedione and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus when treatment with both pioglitazone and metformin is appropriate. (<a href="#i4i_indications_id_5462a006-c0ad-4d56-931c-68173c98e506">1</a>, <a href="#i4i_clinical_studies_id_4f919de5-f3dd-41b3-960f-3dda207644eb">14</a>)  </p>
<p class="Highlighta">Important Limitations of Use: </p>
<dl>
<dt>•</dt>
<dd>Not for treatment of type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>. (<a href="#i4i_indications_id_5462a006-c0ad-4d56-931c-68173c98e506">1</a>)</dd>
</dl>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>Individualize the starting dose of pioglitazone and metformin hydrochloride tablets based on the patient’s current regimen. (<a href="#i4i_dosage_admin_id_1c91f6d5-c9de-422b-bc2e-73af14091222">2</a>) </dd>
<dt>•</dt>
<dd>May adjust the dosing based on effectiveness and tolerability while not exceeding the maximum recommended daily dose of pioglitazone 45 mg and metformin 2550 mg. (<a href="#i4i_dosage_admin_id_1c91f6d5-c9de-422b-bc2e-73af14091222">2</a>)</dd>
<dt>•</dt>
<dd>Pioglitazone and metformin hydrochloride tablets should be given in divided daily doses with meals to reduce the gastrointestinal (GI) side effects due to metformin. (<a href="#i4i_dosage_admin_id_1c91f6d5-c9de-422b-bc2e-73af14091222">2</a>) </dd>
<dt>•</dt>
<dd>Dose increases should be accompanied by careful monitoring for adverse events related to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. (<a href="#i4i_dosage_admin_id_1c91f6d5-c9de-422b-bc2e-73af14091222">2</a>) </dd>
<dt>•</dt>
<dd>Obtain liver tests before starting pioglitazone and metformin hydrochloride tablets. If abnormal, use caution when treating with pioglitazone and metformin hydrochloride tablets, investigate the probable cause, treat (if possible) and follow appropriately. Monitoring liver tests while on pioglitazone and metformin hydrochloride tablets is not recommended in patients without liver disease. (<a href="#i4i_section_id_9cd1f475-f0cc-4e5d-9581-d9d82e8ca411">5.5</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 15 mg pioglitazone/500 mg metformin HCl and 15 mg pioglitazone/850 mg metformin HCl (<a href="#i4i_dosage_form_strength_id_99c76485-dee0-4ca9-adc0-7900d76ee08d">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Initiation in patients with established New York Heart Association (NYHA) Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> [<span class="Italics">see <a href="#i4i_boxed_warning_id_3f104af2-1fd3-45c7-b374-dea16ef6decd">Boxed Warning</a></span>]. (<a href="#i4i_contraindications_id_6c47db78-3491-47bd-9c0c-26d9274bba72">4</a>) </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>.  (<a href="#i4i_contraindications_id_6c47db78-3491-47bd-9c0c-26d9274bba72">4</a>)</dd>
<dt>•</dt>
<dd>Use in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to pioglitazone, metformin or any other component of pioglitazone and metformin hydrochloride tablets. (<a href="#i4i_contraindications_id_6c47db78-3491-47bd-9c0c-26d9274bba72">4</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic acidosis</span>, including <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>. (<a href="#i4i_contraindications_id_6c47db78-3491-47bd-9c0c-26d9274bba72">4</a>, <a href="#i4i_section_id_75c7c85e-1104-4b47-ac01-1d2707206413">5.2</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span>: <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> may occur and can exacerbate or lead to <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Combination use with insulin and use in <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> NYHA Class I and II may increase risk. Monitor patients for signs and symptoms. (<a href="#i4i_section_id_8177ec74-2b3c-4e22-8fca-6355648bc970">5.1</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span>: Warn against excessive alcohol intake. Pioglitazone and metformin hydrochloride tablets are not recommended in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and are contraindicated in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Ensure normal renal function before initiating and at least annually thereafter. (<a href="#i4i_section_id_75c7c85e-1104-4b47-ac01-1d2707206413">5.2</a>, <a href="#i4i_section_id_190c7853-af03-4d5e-8911-dba4ee447bec">5.10</a>) </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>: Dose-related <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> may occur. (<a href="#i4i_section_id_249a319e-1d6f-459b-bec4-278bcb091e7a">5.3</a>) </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>: When used with insulin or an insulin secretagogue, a lower dose of the insulin or insulin secretagogue may be needed to reduce the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. (<a href="#i4i_section_id_d84d70f3-d85d-4535-b791-a08e83467b25">5.4</a>)</dd>
<dt>•</dt>
<dd>Hepatic effects: Postmarketing reports of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, sometimes fatal. Causality cannot be excluded. If <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> is detected, promptly interrupt pioglitazone and metformin hydrochloride tablets and assess patient for probable cause, then treat cause if possible, to resolution or stabilization. Do not restart pioglitazone and metformin hydrochloride tablets if <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> is confirmed and no alternate etiology can be found. (<a href="#i4i_section_id_9cd1f475-f0cc-4e5d-9581-d9d82e8ca411">5.5</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">Bladder cancer</span>: Preclinical and clinical trial data, and results from an observational study suggest an increased risk of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> in pioglitazone users. The observational data further suggest that the risk increases with duration of use. Do not use in patients with active <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>. Use caution when using in patients with a prior history of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>. (<a href="#_RefID645DAC44E5B448C7A66684319DD53139">5.6</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span>: Increased incidence in female patients. Apply current standards of care for assessing and maintaining bone health. (<a href="#i4i_section_id_7e61b83e-e339-4a5d-be77-229a84c0be0d">5.7</a>) </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular edema</span>: Postmarketing reports. Recommend regular eye exams in all patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> according to current standards of care with prompt evaluation for acute visual changes. (<a href="#i4i_section_id_dc99b8df-1fd4-409c-922c-c9c03305bbcd">5.8</a>) </dd>
<dt>•</dt>
<dd>Temporarily discontinue in patients undergoing radiologic studies with intravascular iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids. (<a href="#i4i_section_id_1493f6ad-b9fd-44e1-aa77-03364469dbdc">5.12</a>) </dd>
<dt>•</dt>
<dd>Vitamin B<span class="Sub">12</span> deficiency: Metformin may lower vitamin B<span class="Sub">12</span> levels. Monitor hematologic parameters annually. (<a href="#i4i_section_id_54ed08aa-475b-4b54-93ba-96f92faa4106">5.14</a>) </dd>
<dt>•</dt>
<dd>Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with pioglitazone and metformin hydrochloride tablets or any other antidiabetic drug. (<a href="#i4i_section_id_5491d17a-c806-442f-96d4-afec633c2ce7">5.15</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (&gt; 5%) are <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. (<a href="#i4i_section_id_ea958dfc-0d84-4561-965f-87c6661b24ed">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact TEVA USA, PHARMACOVIGILANCE at 1-866-832-8537, or drug.safety@tevapharm.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Strong CYP2C8 inhibitors (e.g., gemfibrozil) increase pioglitazone concentrations. Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (<a href="#i4i_section_id_a213629f-661b-4969-9f42-971871d9844e">2.3</a>, <a href="#i4i_section_id_d3254fd0-d618-417d-8d53-4556a0126bf8">7.1</a>) </dd>
<dt>•</dt>
<dd>CYP2C8 inducers (e.g., rifampin) may decrease pioglitazone concentrations. (<a href="#i4i_section_id_0b390350-8d95-4454-b0c8-8bfc9d238461">7.2</a>)</dd>
<dt>•</dt>
<dd>Cationic drugs: May reduce metformin elimination. Use with caution in patients who are taking cationic medications eliminated by renal tubular secretion. (<a href="#i4i_section_id_a155d100-3328-4c75-8aec-00600b51f4ee">7.4</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Nursing mothers: Discontinue drug or nursing, taking into consideration the importance of the drug to the mother. (<a href="#i4i_nursing_mothers_id_1a358896-99c4-48c7-a7c5-e8472eb9cd74">8.3</a>)</dd>
<dt>•</dt>
<dd>Pediatrics: Not recommended for use in pediatric patients. (<a href="#i4i_pediatric_use_id_ed0239f2-e5ad-48a2-a3f6-8a3714154972">8.4</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 6/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span> AND <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc"><span class="Bold">Important Limitations of Use</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommendations for All Patients</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Concomitant Use With an Insulin Secretagogue or Insulin</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Concomitant Use With Strong CYP2C8 Inhibitors</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> </a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Hepatic Effects </a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Urinary Bladder Tumors </a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span> </a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span> </a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Ovulation </a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Monitoring of Renal Function </a></h2>
<h2><a href="#section-5.11" class="toc">5.11 <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">Hypoxic</span> States </a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Surgical Procedures </a></h2>
<h2><a href="#section-5.13" class="toc">5.13 Alcohol Intake </a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Vitamin B<span class="Sub">12</span> Levels </a></h2>
<h2><a href="#section-5.15" class="toc">5.15 Macrovascular Outcomes </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience </a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold">Laboratory Abnormalities </span></a></h2>
<h2><a href="#section-6.3" class="toc">6.2 Postmarketing Experience </a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Strong CYP2C8 Inhibitors </a></h2>
<h2><a href="#section-7.2" class="toc">7.2 CYP2C8 Inducers </a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Carbonic Anhydrase Inhibitors </a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Cationic Drugs </a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Drugs Affecting Glycemic Control </a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Patients Who Have Inadequate Glycemic Control with Diet and Exercise Alone</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Patients Previously Treated With Metformin </a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="i4i_boxed_warning_id_3f104af2-1fd3-45c7-b374-dea16ef6decd"></a><a name="section-1"></a><p></p>
<h1>WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span> AND <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span></h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> </span></p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Thiazolidinediones, including pioglitazone, which is a component of pioglitazone and metformin hydrochloride tablets, cause or exacerbate <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> in some patients [<span class="Italics">see Warnings and Precautions</span> (<a href="#i4i_section_id_8177ec74-2b3c-4e22-8fca-6355648bc970">5.1</a>)]. </span></dd>
<dt>•</dt>
<dd><span class="Bold">After initiation of pioglitazone and metformin hydrochloride tablets, and after dose increases, monitor patients carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (e.g., excessive, rapid <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and/or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>). If <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> develops, it should be managed according to current standards of care and discontinuation or dose reduction of pioglitazone and metformin hydrochloride tablets must be considered [<span class="Italics">see Warnings and Precautions</span> (<a href="#i4i_section_id_8177ec74-2b3c-4e22-8fca-6355648bc970">5.1</a>)]. </span></dd>
<dt>•</dt>
<dd><span class="Bold">Pioglitazone and metformin hydrochloride tablets are not recommended in patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. </span></dd>
<dt>•</dt>
<dd><span class="Bold">Initiation of pioglitazone and metformin hydrochloride tablets in patients with established New York Heart Association (NYHA) Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is contraindicated [<span class="Italics">see Contraindications (<a href="#i4i_contraindications_id_6c47db78-3491-47bd-9c0c-26d9274bba72">4</a>) and Warnings and Precautions (<a href="#i4i_section_id_8177ec74-2b3c-4e22-8fca-6355648bc970">5.1</a>)</span>]. </span></dd>
</dl>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span></span></p>
<dl>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a rare but serious complication that can occur due to metformin accumulation. The risk increases with conditions such as <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, excess alcohol intake, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> [<span class="Italics">see Warnings and Precautions</span> (<a href="#i4i_section_id_75c7c85e-1104-4b47-ac01-1d2707206413">5.2</a>)]. </span></dd>
<dt>•</dt>
<dd><span class="Bold">The onset is often subtle, accompanied only by nonspecific symptoms such as <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, increasing <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and nonspecific <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>. Laboratory abnormalities include low pH, increased <span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span>, and elevated blood lactate [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_75c7c85e-1104-4b47-ac01-1d2707206413">5.2</a>)</span>].</span></dd>
<dt>•</dt>
<dd><span class="Bold">If <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> is suspected, pioglitazone and metformin hydrochloride tablets should be discontinued and the patient hospitalized immediately [<span class="Italics">see Warnings and Precautions</span> (<a href="#i4i_section_id_75c7c85e-1104-4b47-ac01-1d2707206413">5.2</a>)].</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_5462a006-c0ad-4d56-931c-68173c98e506"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Pioglitazone and metformin hydrochloride tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus when treatment with both pioglitazone and metformin is appropriate [<span class="Italics">see Clinical Studies (<a href="#i4i_clinical_studies_id_4f919de5-f3dd-41b3-960f-3dda207644eb">14</a>)</span>].</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d9f40df8-f835-47b8-b7a5-e27b8c1c0cc5"></a><a name="section-1.1"></a><p></p>
<h2><span class="Bold">Important Limitations of Use</span></h2>
<p class="First">Pioglitazone exerts its antihyperglycemic effect only in the presence of endogenous insulin. Pioglitazone and metformin hydrochloride tablets USP should not be used to treat type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>, as it would not be effective in these settings. </p>
<p>Use caution in patients with liver disease [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_9cd1f475-f0cc-4e5d-9581-d9d82e8ca411">5.5</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_1c91f6d5-c9de-422b-bc2e-73af14091222"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_55bb8ff6-ce89-470c-a9ee-645d49029a7d"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommendations for All Patients</h2>
<p class="First">Pioglitazone and metformin hydrochloride tablets should be taken with meals to reduce the gastrointestinal side effects associated with metformin.</p>
<p>If therapy with a combination tablet containing pioglitazone and metformin is considered appropriate the recommended starting dose is: </p>
<dl>
<dt>•</dt>
<dd>15 mg/500 mg twice daily or 15 mg/850 mg once daily and gradually titrated, as needed, after assessing adequacy of therapeutic response and tolerability, </dd>
<dt>•</dt>
<dd>for patients with New York Heart Association (NYHA) Class I or Class II <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>: 15 mg/500 mg or 15 mg/850 mg once daily and gradually titrated, as needed, after assessing adequacy of therapeutic response and tolerability, </dd>
<dt>•</dt>
<dd>for patients inadequately controlled on metformin monotherapy: 15 mg/500 mg twice daily or 15 mg/850 mg once or twice daily (depending on the dose of metformin already being taken) and gradually titrated, as needed, after assessing adequacy of therapeutic response and tolerability, </dd>
<dt>•</dt>
<dd>for patients inadequately controlled on pioglitazone monotherapy: 15 mg/500 mg twice daily or 15 mg/850 mg once daily and gradually titrated, as needed, after assessing adequacy of therapeutic response and tolerability. </dd>
<dt>•</dt>
<dd>for patients who are changing from combination therapy of pioglitazone plus metformin as separate tablets: pioglitazone and metformin hydrochloride tablets should be taken at doses that are as close as possible to the dose of pioglitazone and metformin already being taken. </dd>
</dl>
<p>Pioglitazone and metformin hydrochloride tablets may be titrated up to a maximum daily dose of 45 mg of pioglitazone and 2550 mg of metformin. </p>
<p>Metformin doses above 2000 mg may be better tolerated given three times a day. </p>
<p>After initiation of pioglitazone and metformin hydrochloride tablets or with dose increase, monitor patients carefully for adverse reactions related to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> such as <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and signs and symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> [<span class="Italics">see <a href="#i4i_boxed_warning_id_3f104af2-1fd3-45c7-b374-dea16ef6decd">Boxed Warning</a> and Warnings and Precautions (<a href="#i4i_section_id_8177ec74-2b3c-4e22-8fca-6355648bc970">5.1</a>)</span>]. Liver tests (serum alanine and <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferases</span>, alkaline phosphatase, and total bilirubin) should be obtained prior to initiating pioglitazone and metformin hydrochloride tablets. Routine periodic monitoring of liver tests during treatment with pioglitazone and metformin hydrochloride tablets is not recommended in patients without liver disease. Patients who have liver test abnormalities prior to initiation of pioglitazone and metformin hydrochloride tablets or who are found to have abnormal liver tests while taking pioglitazone and metformin hydrochloride tablets should be managed as described under Warnings and Precautions [<span class="Italics">see Warnings and Precautions (</span><span class="Italics"><a href="#i4i_section_id_9cd1f475-f0cc-4e5d-9581-d9d82e8ca411">5.5</a></span><span class="Italics">) and Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_6b289b9c-e13b-4de0-9850-a6a18dc42bad">12.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_72878b2a-bfd3-409a-8394-d2a871e344e0"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Concomitant Use With an Insulin Secretagogue or Insulin</h2>
<p class="First">If <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> occurs in a patient coadministered pioglitazone and metformin hydrochloride tablets and an insulin secretagogue (e.g., sulfonylurea), the dose of the insulin secretagogue should be reduced. </p>
<p>If <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> occurs in a patient coadministered pioglitazone and metformin hydrochloride tablets and insulin, the dose of insulin should be decreased by 10% to 25%. Further adjustments to the insulin dose should be individualized based on glycemic response.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a213629f-661b-4969-9f42-971871d9844e"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Concomitant Use With Strong CYP2C8 Inhibitors</h2>
<p class="First">Coadministration of pioglitazone (one of the ingredients in pioglitazone and metformin hydrochloride tablets) and gemfibrozil, a strong CYP2C8 inhibitor, increases pioglitazone exposure approximately 3 fold. Therefore, the maximum recommended dose of pioglitazone and metformin hydrochloride tablets are 15 mg/850 mg daily when used in combination with gemfibrozil or other strong CYP2C8 inhibitors [<span class="Italics">see Drug Interactions (<a href="#i4i_section_id_d3254fd0-d618-417d-8d53-4556a0126bf8">7.1</a>) and Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_6b289b9c-e13b-4de0-9850-a6a18dc42bad">12.3</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_99c76485-dee0-4ca9-adc0-7900d76ee08d"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<dl>
<dt>•</dt>
<dd>15 mg (base) and 500 mg: white to off-white, oval-shaped tablet, film-coated, debossed with "TV" on one side of the tablet and "7677" on the other side.</dd>
<dt>•</dt>
<dd>15 mg (base) and 850 mg: white to off-white, oval-shaped tablet, film-coated, debossed with "TV" on one side of the tablet and "7678" on the other side.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_6c47db78-3491-47bd-9c0c-26d9274bba72"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<dl>
<dt>•</dt>
<dd>Initiation in patients with established NYHA Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> [<span class="Italics">see <a href="#i4i_boxed_warning_id_3f104af2-1fd3-45c7-b374-dea16ef6decd">Boxed Warning</a></span>].</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> (e.g., serum creatinine levels ≥ 1.5 mg/dL [males], ≥ 1.4 mg/dL [females], or abnormal creatinine clearance) which may also result from conditions such as <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span> (<span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>), <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span> [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_75c7c85e-1104-4b47-ac01-1d2707206413">5.2</a>, <a href="#i4i_section_id_190c7853-af03-4d5e-8911-dba4ee447bec">5.10</a>)</span>]. </dd>
<dt>•</dt>
<dd>Use in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to pioglitazone, metformin, or any other component of pioglitazone and metformin hydrochloride tablets. </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic acidosis</span>, including <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>. <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">Diabetic ketoacidosis</span> should be treated with insulin. </dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_6b3adf65-1552-4b86-b99a-a1c9cb4fb2d7"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8177ec74-2b3c-4e22-8fca-6355648bc970"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span></h2>
<p class="First"><span class="Bold">Pioglitazone</span></p>
<p>Pioglitazone, like other thiazolidinediones, can cause dose-related <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> when used alone or in combination with other antidiabetic medications and is most common when pioglitazone is used in combination with insulin. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> may lead to or exacerbate <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Patients treated with pioglitazone and metformin hydrochloride tablets should be observed for signs and symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. If <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> develops, it should be managed according to current standards of care and discontinuation or dose reduction of pioglitazone and metformin hydrochloride tablets must be considered [<span class="Italics">see <a href="#i4i_boxed_warning_id_3f104af2-1fd3-45c7-b374-dea16ef6decd">Boxed Warning</a>, Contraindications (<a href="#i4i_contraindications_id_6c47db78-3491-47bd-9c0c-26d9274bba72">4</a>), and Adverse Reactions (<a href="#i4i_section_id_ea958dfc-0d84-4561-965f-87c6661b24ed">6.1</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_75c7c85e-1104-4b47-ac01-1d2707206413"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span></h2>
<p class="First"><span class="Bold">Metformin hydrochloride</span></p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span></span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a serious, metabolic complication that can occur due to metformin accumulation during treatment with pioglitazone and metformin hydrochloride tablets and it is fatal in approximately 50% of cases. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> may also occur in association with a number of pathophysiologic conditions, including <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and whenever there is significant tissue <span class="product-label-link" type="condition" conceptid="4131044" conceptname="Hypoperfusion">hypoperfusion</span> and <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is characterized by elevated blood lactate concentrations (&gt; 5 mmol/L), decreased blood pH, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span> with an increased <span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span>, and an increased lactate/<span class="product-label-link" type="condition" conceptid="4029769" conceptname="Pyruvic acid">pyruvate</span> ratio. When metformin is implicated as the cause of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, metformin plasma levels &gt; 5 mcg/mL are generally found. </p>
<p>The reported incidence of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> in patients receiving metformin hydrochloride is approximately 0.03 cases/1000 patient-years, with approximately 0.015 fatal cases/1000 patient-years. In more than 20,000 patient-years, exposure to metformin in clinical trials, there were no reports of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. Reported cases have occurred primarily in diabetic patients with significant <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, including both intrinsic <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> and renal <span class="product-label-link" type="condition" conceptid="4131044" conceptname="Hypoperfusion">hypoperfusion</span>, often in the setting of multiple concomitant medical/surgical problems and multiple concomitant medications. Patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> requiring pharmacologic management, particularly when accompanied by <span class="product-label-link" type="condition" conceptid="4131044" conceptname="Hypoperfusion">hypoperfusion</span> and <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>, are at increased risk of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. The risk of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> increases with the degree of renal dysfunction and the patient's age. The risk of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> may, therefore, be significantly decreased by regular monitoring of renal function in patients taking metformin. In particular, treatment of the elderly should be accompanied by careful monitoring of renal function. Pioglitazone and metformin hydrochloride tablets treatment should not be initiated in any patient unless measurement of creatinine clearance demonstrates that renal function is not reduced. In addition, metformin should be promptly withheld in the presence of any condition associated with <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, or <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>. Because impaired hepatic function may significantly limit the ability to clear lactate, metformin should generally be avoided in patients with clinical or laboratory evidence of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Patients should be cautioned against excessive alcohol intake when taking metformin, because alcohol potentiates the effects of metformin on lactate metabolism. In addition, metformin should be temporarily discontinued prior to any intravascular radiocontrast study and for any surgical procedure necessitating restricted intake of food or fluids [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_190c7853-af03-4d5e-8911-dba4ee447bec">5.10</a>, <a href="#i4i_section_id_96ba1215-d356-45fd-b46e-2e82282b1993">5.11</a>, <a href="#i4i_section_id_1493f6ad-b9fd-44e1-aa77-03364469dbdc">5.12</a>, <a href="#i4i_section_id_400e2dd6-31b1-46e3-8162-6ea5c907e32d">5.13</a>)</span>]. Use of topiramate, a carbonic anhydrase inhibitor, in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> prophylaxis may frequently cause dose-dependent <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> and may exacerbate the risk of metformin-induced <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> [<span class="Italics">see Drug Interactions (<a href="#i4i_section_id_d3254fd0-d618-417d-8d53-4556a0126bf8">7.1</a>) and Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_6b289b9c-e13b-4de0-9850-a6a18dc42bad">12.3</a>)</span>]. </p>
<p>The onset of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> often is subtle, and accompanied only by nonspecific symptoms such as <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, increasing <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and nonspecific <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>. There may be associated <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and resistant <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmias</span> with more marked <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>. Patients should be educated to promptly report these symptoms should they occur. If present, pioglitazone and metformin hydrochloride tablets should be withdrawn until <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> is ruled out. Serum electrolytes, <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span>, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful. Once a patient is stabilized on any dose level of metformin, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, which are common during initiation of therapy, are unlikely to recur. Later occurrence of <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> could be due to <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or other serious disease. </p>
<p>Levels of fasting venous plasma lactate above the upper limit of normal but less than 5 mmol/L in patients taking metformin do not necessarily indicate impending <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> and may be explainable by other mechanisms, such as poorly controlled <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, vigorous physical activity, or technical problems in sample handling [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_190c7853-af03-4d5e-8911-dba4ee447bec">5.10</a>)</span>]. </p>
<p><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> should be suspected in any diabetic patient with <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> lacking evidence of <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span> (<span class="product-label-link" type="condition" conceptid="4171926" conceptname="Ketonuria">ketonuria</span> and <span class="product-label-link" type="condition" conceptid="4060404" conceptname="Acetonemia">ketonemia</span>). </p>
<p><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a medical emergency that must be treated in a hospital setting. In a patient with <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> who is taking metformin, the drug should be discontinued immediately and general supportive measures promptly instituted. Because metformin hydrochloride is dialyzable (with a clearance of up to 170 mL/min under good hemodynamic conditions), prompt hemodialysis is recommended to correct the <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> and remove the accumulated metformin. Such management often results in prompt reversal of symptoms and recovery [<span class="Italics">see Contraindications (<a href="#i4i_contraindications_id_6c47db78-3491-47bd-9c0c-26d9274bba72">4</a>) and Warnings and Precautions (<a href="#i4i_section_id_190c7853-af03-4d5e-8911-dba4ee447bec">5.10</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_249a319e-1d6f-459b-bec4-278bcb091e7a"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h2>
<p class="First">In controlled clinical trials with pioglitazone, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> was reported more frequently in patients treated with pioglitazone than in placebo-treated patients and is dose related [<span class="Italics">see Adverse Reactions (<a href="#i4i_section_id_ea958dfc-0d84-4561-965f-87c6661b24ed">6.1</a>)</span>]. In postmarketing experience, reports of new onset or worsening of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been received. </p>
<p>Pioglitazone and metformin hydrochloride tablets should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. Because thiazolidinediones, including pioglitazone, can cause <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, which can exacerbate or lead to <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, pioglitazone and metformin hydrochloride tablets should be used with caution in patients at risk for <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Patients treated with pioglitazone and metformin hydrochloride tablets should be monitored for signs and symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> [<span class="Italics">see <a href="#i4i_boxed_warning_id_3f104af2-1fd3-45c7-b374-dea16ef6decd">Boxed Warning</a>, Warnings and Precautions (<a href="#i4i_section_id_8177ec74-2b3c-4e22-8fca-6355648bc970">5.1</a>), and Patient Counseling Information (<a href="#_RefID5EB84781E56946E29AFE3339F7E0AD15">17.1</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d84d70f3-d85d-4535-b791-a08e83467b25"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> </h2>
<p class="First">Patients receiving pioglitazone and metformin hydrochloride tablets in combination with insulin or other antidiabetic medications (particularly insulin secretagogues such as sulfonylureas) may be at risk for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. A reduction in the dose of the concomitant antidiabetic medication may be necessary to reduce the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_72878b2a-bfd3-409a-8394-d2a871e344e0">2.2</a>)</span>]. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> can also occur when caloric intake is deficient or when strenuous exercise is not compensated by caloric supplement. Elderly, debilitated, or malnourished patients, and those with adrenal or <span class="product-label-link" type="condition" conceptid="4254542" conceptname="Hypopituitarism">pituitary insufficiency</span> or alcohol <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> are particularly susceptible to hypoglycemic effects. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> may be difficult to recognize in the elderly, and in people who are taking beta-adrenergic blocking drugs. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9cd1f475-f0cc-4e5d-9581-d9d82e8ca411"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Hepatic Effects </h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">There have been postmarketing reports of fatal and nonfatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> in patients taking pioglitazone, although the reports contain insufficient information necessary to establish the probable cause. </span>There has been no evidence of drug-induced hepatotoxicity in the pioglitazone controlled clinical trial database to date [<span class="Italics">see Adverse Reactions</span> (<span class="Italics"><a href="#i4i_section_id_ea958dfc-0d84-4561-965f-87c6661b24ed">6.1</a></span>)].  </p>
<p>Patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> may have <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">fatty liver</span> disease or cardiac disease with episodic <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, both of which may cause liver test abnormalities, and they may also have other forms of liver disease, many of which can be treated or managed. Therefore, obtaining a liver test panel (serum <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> [ALT], <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> [AST], alkaline phosphatase, and total bilirubin) and assessing the patient is recommended before initiating pioglitazone and metformin hydrochloride tablets therapy. </p>
<p>In patients with abnormal liver tests, pioglitazone and metformin hydrochloride tablets should be initiated with caution. </p>
<p>Measure liver tests promptly in patients who report symptoms that may indicate <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, including <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, right <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">upper abdominal discomfort</span>, dark urine or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. In this clinical context, if the patient is found to have abnormal liver tests (ALT greater than three times the upper limit of the reference range), pioglitazone and metformin hydrochloride tablets treatment should be interrupted and investigation done to establish the probable cause. Pioglitazone and metformin hydrochloride tablets should not be restarted in these patients without another explanation for the liver test abnormalities. </p>
<p>Patients who have serum ALT greater than three times the reference range with serum total bilirubin greater than two times the reference range without alternative etiologies are at risk for severe drug-induced <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, and should not be restarted on pioglitazone and metformin hydrochloride tablets. For patients with lesser elevations of serum ALT or bilirubin and with an alternate probable cause, treatment with pioglitazone and metformin hydrochloride tablets can be used with caution. </p>
<p>Because impaired hepatic function has been associated with some cases of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> pioglitazone and metformin hydrochloride tablets should generally be avoided in patients with clinical or laboratory evidence of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_645dac44-e5b4-48c7-a666-84319dd53139"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Urinary Bladder Tumors </h2>
<p class="First">Tumors were observed in the urinary bladder of male rats in the two-year carcinogenicity study [<span class="Italics">see Nonclinical Toxicology</span><span class="Italics">(<a href="#i4i_carcinogenesis_mutagenesis_fertility_id_83434e02-87f4-48d8-b22d-9553b9c8bd59">13.1</a>)</span>]. In two 3 year trials in which pioglitazone was compared to placebo or glyburide, there were 16/3656 (0.44%) reports of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> in patients taking pioglitazone compared to 5/3679 (0.14%) in patients not taking pioglitazone. After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>, there were six (0.16%) cases on pioglitazone and two (0.05%) cases on placebo.  </p>
<p>A five-year interim report of an ongoing 10 year observational cohort study found a nonsignificant increase in the risk for <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> in subjects ever exposed to pioglitazone, compared to subjects never exposed to pioglitazone (HR 1.2 [95% CI 0.9 to 1.5]). Compared to never exposure, a duration of pioglitazone therapy longer than 12 months was associated with an increase in risk (HR 1.4 [95% CI 0.9 to 2.1]), which reached statistical significance after more than 24 months of pioglitazone use (HR 1.4 [95% CI 1.03 to 2.0]). Interim results from this study suggested that taking pioglitazone longer than 12 months increased the relative risk of developing <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> in any given year by 40%, which equates to an absolute increase of three cases in 10,000 (from approximately seven in 10,000 [without pioglitazone] to approximately 10 in 10,000 [with pioglitazone]). </p>
<p>There are insufficient data to determine whether pioglitazone is a tumor promoter for urinary bladder tumors. Consequently, pioglitazone and metformin hydrochloride tablets should not be used in patients with active <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> and the benefits of glycemic control versus unknown risks for cancer recurrence with pioglitazone and metformin hydrochloride tablets should be considered in patients with a prior history of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7e61b83e-e339-4a5d-be77-229a84c0be0d"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span> </h2>
<p class="First">In PROactive (the Prospective Pioglitazone Clinical Trial in Macrovascular Events), 5238 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and a history of macrovascular disease were randomized to pioglitazone (N = 2605), force-titrated up to 45 mg daily or placebo (N = 2633) in addition to standard of care. During a mean follow-up of 34.5 months, the incidence of bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> in females was 5.1% (44/870) for pioglitazone versus 2.5% (23/905) for placebo. This difference was noted after the first year of treatment and persisted during the course of the study. The majority of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> observed in female patients were nonvertebral <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> including lower limb and distal upper limb. No increase in the incidence of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> was observed in men treated with pioglitazone (1.7%) versus placebo (2.1%). The risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> should be considered in the care of patients, especially female patients, treated with pioglitazone and metformin hydrochloride tablets and attention should be given to assessing and maintaining bone health according to current standards of care. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dc99b8df-1fd4-409c-922c-c9c03305bbcd"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span> </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular edema</span> has been reported in postmarketing experience in diabetic patients who were taking pioglitazone or another thiazolidinedione. Some patients presented with <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> or decreased visual acuity, but others were diagnosed on routine ophthalmologic examination.</p>
<p>Most patients had <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> at the time <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span> was diagnosed. Some patients had improvement in their <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span> after discontinuation of the thiazolidinedione. </p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> should have regular eye exams by an ophthalmologist according to current standards of care. Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> who report any visual symptoms should be promptly referred to an ophthalmologist, regardless of the patient's underlying medications or other physical findings [<span class="Italics">see Adverse Reactions (<a href="#i4i_section_id_ea958dfc-0d84-4561-965f-87c6661b24ed">6.1</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_56110353-dd59-4bad-bd99-c7e4722b1643"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Ovulation </h2>
<p class="First">Therapy with pioglitazone, like other thiazolidinediones, may result in ovulation in some premenopausal anovulatory women. As a result, these patients may be at an increased risk for pregnancy while taking pioglitazone and metformin hydrochloride tablets [<span class="Italics">see Use in Specific Populations (<a href="#i4i_pregnancy_id_1f238f87-2a92-40d2-a413-09661c872343">8.1</a>)</span>]. This effect has not been investigated in clinical trials, so the frequency of this occurrence is not known. Adequate contraception in all premenopausal women treated with pioglitazone and metformin hydrochloride tablets is recommended. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_190c7853-af03-4d5e-8911-dba4ee447bec"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Monitoring of Renal Function </h2>
<p class="First">Metformin is substantially excreted by the kidney, and the risk of metformin accumulation and <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> increases with the degree of impairment of renal function. Therefore, pioglitazone and metformin hydrochloride tablets are contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. </p>
<p>Before initiation of therapy with pioglitazone and metformin hydrochloride tablets and at least annually thereafter, renal function should be assessed and verified as normal. In patients in whom development of renal dysfunction is anticipated (e.g., elderly), renal function should be assessed more frequently and pioglitazone and metformin hydrochloride tablets discontinued if evidence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is present. </p>
<p><span class="Bold">Use of Concomitant Medications That May Affect Renal Function or Metformin Disposition</span></p>
<p>Concomitant medication(s) that may affect renal function or result in significant hemodynamic change or may interfere with the disposition of metformin, such as cationic drugs that are eliminated by renal tubular secretion, should be used with caution [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_6b289b9c-e13b-4de0-9850-a6a18dc42bad">12.3</a>)</span>]. </p>
<p><span class="Bold">Radiological Studies and Surgical Procedures</span></p>
<p>Radiologic studies involving the use of intravascular iodinated contrast materials (for example, intravenous urogram, intravenous cholangiography, angiography, and computed tomography (CT) scans with intravascular contrast materials) can lead to acute alteration of renal function and have been associated with <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> in patients receiving metformin [<span class="Italics">see Contraindications (<a href="#i4i_contraindications_id_6c47db78-3491-47bd-9c0c-26d9274bba72">4</a>)</span>]. Therefore, in patients in whom any such study is planned, pioglitazone and metformin hydrochloride tablets should be discontinued at the time of or prior to the procedure, and withheld for 48 hours subsequent to the procedure and reinstituted only after renal function has been re-evaluated and found to be normal. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_96ba1215-d356-45fd-b46e-2e82282b1993"></a><a name="section-5.11"></a><p></p>
<h2>5.11 <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">Hypoxic</span> States </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">Cardiovascular collapse</span> (<span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>) from whatever cause, acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> and other conditions characterized by <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span> have been associated with <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> and may also cause prerenal <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>. When such events occur in patients receiving pioglitazone and metformin hydrochloride tablets therapy, the drug should be promptly discontinued. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1493f6ad-b9fd-44e1-aa77-03364469dbdc"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Surgical Procedures </h2>
<p class="First">Use of pioglitazone and metformin hydrochloride tablets should be temporarily suspended for any surgical procedure (except minor procedures not associated with restricted intake of food and fluids) and should not be restarted until the patient's oral intake has resumed and renal function has been evaluated as normal. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_400e2dd6-31b1-46e3-8162-6ea5c907e32d"></a><a name="section-5.13"></a><p></p>
<h2>5.13 Alcohol Intake </h2>
<p class="First">Alcohol is known to potentiate the effect of metformin on lactate metabolism. Patients, therefore, should be warned against excessive alcohol intake, acute or chronic, while receiving pioglitazone and metformin hydrochloride tablets. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_54ed08aa-475b-4b54-93ba-96f92faa4106"></a><a name="section-5.14"></a><p></p>
<h2>5.14 Vitamin B<span class="Sub">12</span> Levels </h2>
<p class="First">In controlled clinical trials of metformin of 29 weeks’ duration, a decrease to subnormal levels of previously normal serum vitamin B<span class="Sub">12</span> levels, without clinical manifestations, was observed in approximately 7% of patients. Such decrease, possibly due to interference with B<span class="Sub">12</span> absorption from the B<span class="Sub">12</span>-intrinsic factor complex, is, however, very rarely associated with <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and appears to be rapidly reversible with discontinuation of metformin or vitamin B<span class="Sub">12</span> supplementation. Measurement of hematologic parameters on an annual basis is advised in patients on pioglitazone and metformin hydrochloride tablets and any apparent abnormalities should be appropriately investigated and managed. Certain individuals (those with inadequate vitamin B<span class="Sub">12</span> or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin B<span class="Sub">12</span> levels. In these patients, routine serum vitamin B<span class="Sub">12</span> measurements at two- to three-year intervals may be useful. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5491d17a-c806-442f-96d4-afec633c2ce7"></a><a name="section-5.15"></a><p></p>
<h2>5.15 Macrovascular Outcomes </h2>
<p class="First" style="border-left:1px solid;">There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with pioglitazone and metformin hydrochloride tablets or any other oral antidiabetic drug.<span class="XmChange">.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_6f00887e-4611-4fa3-b3ef-2ae3cc4db94c"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed elsewhere in the labeling: </p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> [<span class="Italics">see <a href="#i4i_boxed_warning_id_3f104af2-1fd3-45c7-b374-dea16ef6decd">Boxed Warning</a> and Warnings and Precautions (<a href="#i4i_section_id_8177ec74-2b3c-4e22-8fca-6355648bc970">5.1</a>)</span>] </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> [<span class="Italics">see <a href="#i4i_boxed_warning_id_3f104af2-1fd3-45c7-b374-dea16ef6decd">Boxed Warning</a> and Warnings and Precautions (<a href="#i4i_section_id_75c7c85e-1104-4b47-ac01-1d2707206413">5.2</a>)</span>] </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_249a319e-1d6f-459b-bec4-278bcb091e7a">5.3</a>)</span>] </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span> [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_7e61b83e-e339-4a5d-be77-229a84c0be0d">5.7</a>)</span>]</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ea958dfc-0d84-4561-965f-87c6661b24ed"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience </h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </p>
<p><span class="Bold">Pioglitazone</span></p>
<p>Over 8500 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> have been treated with pioglitazone in randomized, double-blind, controlled clinical trials, including 2605 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and macrovascular disease treated with pioglitazone from the PROactive clinical trial. In these trials, over 6000 patients have been treated with pioglitazone for six months or longer, over 4500 patients have been treated with pioglitazone for one year or longer, and over 3000 patients have been treated with pioglitazone for at least two years. </p>
<p>In six pooled 16 to 26 week placebo-controlled monotherapy and 16 to 24 week add-on combination therapy trials, the incidence of withdrawals due to adverse events was 4.5% for patients treated with pioglitazone and 5.8% for comparator-treated patients. The most common adverse events leading to withdrawal were related to inadequate glycemic control, although the incidence of these events was lower (1.5%) with pioglitazone than with placebo (3.0%). </p>
<p>In the PROactive trial, the incidence of withdrawals due to adverse events was 9.0% for patients treated with pioglitazone and 7.7% for placebo-treated patients. <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> was the most common serious adverse event leading to withdrawal occurring in 1.3% of patients treated with pioglitazone and 0.6% of patients treated with placebo. </p>
<p><span class="Bold"><span class="Italics">Common Adverse Events: 16 to 26 Week Monotherapy Trials</span></span></p>
<p>A summary of the incidence and type of common adverse events reported in three pooled 16 to 26 week placebo-controlled monotherapy trials of pioglitazone is provided in <span class="Bold">Table 1</span>. Terms that are reported represent those that occurred at an incidence of &gt; 5% and more commonly in patients treated with pioglitazone than in patients who received placebo. None of these adverse events were related to the pioglitazone dose.</p>
<table width="100%">
<caption><span>Table 1: Three Pooled 16 to 26 Week Placebo-Controlled Clinical Trials of Pioglitazone Monotherapy: Adverse Events Reported at an Incidence &gt; 5% and More Commonly in Patients Treated With Pioglitazone Than in Patients Treated With Placebo</span></caption>
<col width="34%">
<col width="16%">
<col width="14%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Toprule"><p class="First"><span class="Bold">% of Patients</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Placebo</span></p>
<p>N = 259</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">Pioglitazone </span></p>
<p>N = 606</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">6.9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">4.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">2.7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.4</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">0.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.1</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics"><br><span class="Bold">Common Adverse Events: 16 to 24 Week Add-on Combination Therapy Trials</span></span></p>
<p>A summary of the overall incidence and types of common adverse events reported in trials of pioglitazone add-on to metformin is provided in <span class="Bold">Table 2</span>. Terms that are reported represent those that occurred at an incidence of &gt; 5% and more commonly with the highest tested dose of pioglitazone.</p>
<table width="100%">
<caption><span>Table 2: 16- to 24- Week Clinical Trials of Pioglitazone Add-on to Metformin</span></caption>
<col width="17%">
<col width="41%">
<col width="41%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" rowspan="3"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">16 Week Placebo-Controlled Trial Adverse Events Reported in &gt; 5% of Patients and More Commonly in Patients Treated with Pioglitazone + Metformin than in Patients Treated with Placebo + Metformin</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">% of Patients</span></p></td></tr>
<tr>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Placebo + Metformin</span></p>
<p>N = 160</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">Pioglitazone 30 mg + Metformin </span></p>
<p>N = 168</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">2.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">1.9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="2"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">24 Week Non-Controlled Double-Blind Trial Adverse Events Reported in &gt; 5% of Patients and More Commonly in Patients Treated with Pioglitazone 45 mg + Metformin than in Patients Treated with Pioglitazone 30 mg + Metformin</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">% of Patients</span></p></td></tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Pioglitazone 30 mg + Metformin</span></p>
<p>N = 411</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">Pioglitazone 45 mg + Metformin</span></p>
<p>N = 416</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">12.4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">5.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">5.4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.8</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Increased</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">2.9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6.7</p></td>
</tr>
</tbody>
</table>
<p>Note: The preferred terms of <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span>, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">pitting edema</span> and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> were combined to form the aggregate term of “edema.? </p>
<p><span class="Bold"><span class="Italics">Common Adverse Events: 24-Week Pioglitazone and Metformin Hydrochloride Tablets Clinical Trial<br></span></span></p>
<p>Table 3 summarizes the incidence and types of adverse reactions reported in a controlled, 24-week double-blind clinical trial of pioglitazone and metformin hydrochloride tablets dosed twice daily in patients with inadequate glycemic control on diet and exercise (N = 600).</p>
<table width="100%">
<caption><span>Table 3: Adverse Events (≥ 5% for Pioglitazone and Metformin Hydrochloride Tablets) Reported by Patients with Inadequate Glycemic Control on Diet and Exercise in a 24-Week Double-Blind Clinical Trial of Pioglitazone and Metformin Hydrochloride Tablets Administered Twice Daily</span></caption>
<col width="11%">
<col width="53%">
<col width="14%">
<col width="14%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="4"><p class="First"><span class="Bold">% of Patients</span></p></td></tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Pioglitazone and Metformin Hydrochloride Tablets<br>15/850 mg<br>Twice Daily </span></p>
<p>N = 201</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">Pioglitazone</span></p>
<p><span class="Bold">15 mg</span></p>
<p><span class="Bold">Twice Daily</span></p>
<p>N=190 </p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">Metformin</span></p>
<p><span class="Bold">850 mg</span></p>
<p><span class="Bold">Twice Daily</span></p>
<p>N=209 </p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">9.0 </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15.3</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">5.5 </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.6 </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.8 </p></td>
</tr>
</tbody>
</table>
<p>In this 24-week trial, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> was reported in 2.0% of patients in the pioglitazone and metformin hydrochloride tablets group, 1.6% in the pioglitazone monotherapy group and 3.3% in the metformin monotherapy group.</p>
<p><span class="Bold"><span class="Italics">Common Adverse Events: PROactive Trial </span></span></p>
<p>A summary of the overall incidence and types of common adverse events reported in the PROactive trial is provided in <span class="Bold">Table 4</span>. Terms that are reported represent those that occurred at an incidence of &gt; 5% and more commonly in patients treated with pioglitazone than in patients who received placebo.</p>
<table width="100%">
<caption><span>Table 4: PROactive Trial: Incidence and Types of Adverse Events Reported in &gt; 5% of Patients Treated With Pioglitazone and More Commonly Than Placebo</span></caption>
<col width="19%">
<col width="11%">
<col width="14%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">% of Patients</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Placebo</span></p>
<p>N = 2633</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">Pioglitazone</span></p>
<p>N = 2605</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">18.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">27.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">15.3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">26.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">6.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in Extremity</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">5.7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">5.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.5</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">5.0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.1</p></td>
</tr>
</tbody>
</table>
<p>Mean duration of patient follow-up was 34.5 months. </p>
<p><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span></span></span></p>
<p>A summary of the incidence of adverse events related to <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> is provided in <span class="Bold">Table 5</span> for the 16 to 24 week add-on to metformin trials. None of the events were fatal.</p>
<table width="100%">
<caption><span>Table 5: Treatment–Emergent Adverse Events of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> (CHF) Patients Treated With Pioglitazone or Placebo Added on to Metformin</span></caption>
<col width="23%">
<col width="15%">
<col width="20%">
<col width="20%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4"><p class="First"><span class="Bold">Number (%) of Patients</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center" colspan="2">
<p class="First"><span class="Bold">Placebo-Controlled Trial</span></p>
<p><span class="Bold">(16 weeks)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">
<p class="First"><span class="Bold">Non-Controlled Double-Blind Trial</span></p>
<p><span class="Bold">(24 weeks)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Placebo + Metformin</span></p>
<p>N = 160</p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Pioglitazone 30 mg + Metformin</span></p>
<p>N = 168</p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Pioglitazone 30 mg + Metformin</span></p>
<p>N = 411</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">Pioglitazone 45 mg + Metformin</span></p>
<p>N = 416</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">At least one <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> event </p></td>
<td class="Botrule Lrule" align="center"><p class="First">0 </p></td>
<td class="Botrule Lrule" align="center"><p class="First">1 (0.6%) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">0 </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 (0.2%) </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Hospitalized </p></td>
<td class="Botrule Lrule" align="center"><p class="First">0 </p></td>
<td class="Botrule Lrule" align="center"><p class="First">1 (0.6%) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">0 </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 (0.2%) </p></td>
</tr>
</tbody>
</table>
<table width="100%">
<caption><span>Table 6: Treatment–Emergent Adverse Events of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> (CHF)</span></caption>
<col width="19%">
<col width="16%">
<col width="15%">
<col width="15%">
<col width="18%">
<col width="18%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="6"><p class="First"><span class="Bold">Patients Treated with Pioglitazone or Placebo Added on to a Sulfonylurea</span></p></td></tr>
<tr>
<td class="Botrule Lrule" rowspan="3"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="5"><p class="First"><span class="Bold">Number (%) of Patients</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" colspan="3"><p class="First"><span class="Bold">Placebo-Controlled Trial (16 weeks)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">Non-Controlled Double-Blind Trial (24 weeks)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Placebo + Sulfonylurea <br></span>N = 187</p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Pioglitazone <br>15 mg + Sulfonylurea <br></span>N = 184</p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Pioglitazone <br>30 mg + Sulfonylurea <br></span>N = 189</p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Pioglitazone <br>30 mg + Sulfonylurea <br></span>N = 351</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">Pioglitazone <br>45 mg + Sulfonylurea</span></p>
<p>N = 351</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">At least one <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> event </p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 (1.1%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1 (0.3%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6 (1.7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Hospitalized </p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 (1.1%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2 (0.6%)</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="6"><p class="First"><span class="Bold">Patients Treated with Pioglitazone or Placebo Added on to Insulin</span></p></td></tr>
<tr>
<td class="Botrule Lrule" rowspan="3"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="5"><p class="First"><span class="Bold">Number (%) of Patients</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" colspan="3">
<p class="First"><span class="Bold">Placebo-Controlled Trial </span></p>
<p><span class="Bold">(16 weeks)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">
<p class="First"><span class="Bold">Non-Controlled Double-Blind Trial </span></p>
<p><span class="Bold">(24 weeks)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Placebo + Insulin</span></p>
<p>N = 187</p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Pioglitazone <br>15 mg + Insulin</span></p>
<p>N = 191</p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Pioglitazone <br>30 mg + Insulin</span></p>
<p>N = 188</p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Pioglitazone <br>30 mg + Insulin</span></p>
<p>N = 345</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">Pioglitazone<br> 45 mg + Insulin</span></p>
<p>N = 345</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">At least one <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> event </p></td>
<td class="Botrule Lrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 (1.0%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 (1.1%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">3 (0.9%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5 (1.4%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Hospitalized </p></td>
<td class="Botrule Lrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 (1.0%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1 (0.5%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1 (0.3%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3 (0.9%)</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="6"><p class="First"><span class="Bold">Patients Treated with Pioglitazone or Placebo Added on to Metformin</span></p></td></tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="5"><p class="First"><span class="Bold">Number (%) of Patients</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center" colspan="3"><p class="First"><span class="Bold">Placebo-Controlled Trial (16 weeks)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">Non-Controlled Double-Blind Trial (24 weeks)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Placebo + Metformin</span></p>
<p>N = 160</p>
</td>
<td class="Botrule Lrule" align="center" colspan="2">
<p class="First"><span class="Bold">Pioglitazone 30 mg + Metformin</span></p>
<p>N = 168</p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Pioglitazone 30 mg + Metformin</span></p>
<p>N = 411</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">Pioglitazone 45 mg + Metformin</span></p>
<p>N = 416</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">At least one <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> event </p></td>
<td class="Botrule Lrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule" align="center" colspan="2"><p class="First">1 (0.6%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 (0.2%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Hospitalized </p></td>
<td class="Botrule Lrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule" align="center" colspan="2"><p class="First">1 (0.6%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 (0.2%)</p></td>
</tr>
</tbody>
</table>
<table width="100%">
<caption><span>Table 7: Treatment–Emergent Adverse Events of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> (CHF) in Patients With NYHA Class II or III <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> Treated With Pioglitazone or Glyburide</span></caption>
<col width="57%">
<col width="14%">
<col width="12%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" rowspan="2"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Number (%) of Subjects</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Pioglitazone</span></p>
<p>N = 262</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">Glyburide</span></p>
<p>N = 256</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to cardiovascular causes (adjudicated) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">5 (1.9%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6 (2.3%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Overnight hospitalization for worsening CHF (adjudicated) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">26 (9.9%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12 (4.7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Emergency room visit for CHF (adjudicated) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">4 (1.5%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3 (1.2%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Patients experiencing CHF progression during study </p></td>
<td class="Botrule Lrule" align="center"><p class="First">35 (13.4%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">21 (8.2%)</p></td>
</tr>
</tbody>
</table>
<p><br><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> events leading to hospitalization that occurred during the PROactive trial are summarized in <span class="Bold">Table 8</span>.</p>
<table width="100%">
<caption><span>Table 8: Treatment–Emergent Adverse Events of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> (CHF) in PROactive Trial</span></caption>
<col width="53%">
<col width="13%">
<col width="14%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Number (%) of Patients</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Placebo</span><br>N = 2633</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">Pioglitazone</span></p>
<p>N = 2605</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">At least one hospitalized <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> event </p></td>
<td class="Botrule Lrule" align="center"><p class="First">108 (4.1%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">149 (5.7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Fatal </p></td>
<td class="Botrule Lrule" align="center"><p class="First">22 (0.8%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">25 (1.0%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Hospitalized, nonfatal </p></td>
<td class="Botrule Lrule" align="center"><p class="First">86 (3.3%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">124 (4.7%)</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics"><br></span><span class="Bold"><span class="Underline">Cardiovascular Safety<br></span></span>In the PROactive trial, 5238 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and a history of macrovascular disease were randomized to pioglitazone (N = 2605), force-titrated up to 45 mg daily or placebo (N = 2633) in addition to standard of care. Almost all patients (95%) were receiving cardiovascular medications (beta blockers, ACE inhibitors, angiotensin II receptor blockers, calcium channel blockers, nitrates, diuretics, aspirin, statins, and fibrates). At baseline, patients had a mean age of 62 years, mean duration of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> of 9.5 years, and mean HbA1c of 8.1%. Mean duration of follow-up was 34.5 months. </p>
<p>The primary objective of this trial was to examine the effect of pioglitazone on mortality and macrovascular morbidity in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus who were at high risk for macrovascular events. The primary efficacy variable was the time to the first occurrence of any event in a cardiovascular composite endpoint that included all-cause mortality, nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI) including silent MI, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndrome</span>, cardiac intervention including coronary artery bypass grafting or percutaneous intervention, major leg amputation above the ankle, and bypass surgery or revascularization in the leg. A total of 514 (19.7%) patients treated with pioglitazone and 572 (21.7%) placebo-treated patients experienced at least one event from the primary composite endpoint (HR 0.90; 95% CI: 0.80, 1.02; p = 0.10). </p>
<p>Although there was no statistically significant difference between pioglitazone and placebo for the three-year incidence of a first event within this composite, there was no increase in mortality or in total macrovascular events with pioglitazone. The number of first occurrences and total individual events contributing to the primary composite endpoint is shown in <span class="Bold">Table 9</span>.</p>
<table width="100%">
<caption><span>Table 9: PROactive Trial: Number of First and Total Events for Each Component Within the Cardiovascular Composite Endpoint</span></caption>
<col width="36%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center" rowspan="2"><p class="First"><span class="Bold">Cardiovascular Events</span></p></td>
<td class="Botrule Lrule Toprule" align="center" colspan="2">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">N = 2633</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">
<p class="First"><span class="Bold">Pioglitazone</span></p>
<p><span class="Bold">N = 2605</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">First Events</span></p>
<p><span class="Bold">n (%)</span></p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Total events</span></p>
<p><span class="Bold">n</span></p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">First Events</span></p>
<p><span class="Bold">n (%)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">Total events</span></p>
<p><span class="Bold">n</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Any event </p></td>
<td class="Botrule Lrule" align="center"><p class="First">572 (21.7)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">900</p></td>
<td class="Botrule Lrule" align="center"><p class="First">514 (19.7)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">803</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">All-cause mortality </p></td>
<td class="Botrule Lrule" align="center"><p class="First">122 (4.6)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">186</p></td>
<td class="Botrule Lrule" align="center"><p class="First">110 (4.2)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">177</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">118 (4.5)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">157</p></td>
<td class="Botrule Lrule" align="center"><p class="First">105 (4.0)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">131</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">96 (3.6)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">119</p></td>
<td class="Botrule Lrule" align="center"><p class="First">76 (2.9)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">92</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">Acute coronary syndrome</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">63 (2.4)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">78</p></td>
<td class="Botrule Lrule" align="center"><p class="First">42 (1.6)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">65</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Cardiac intervention (CABG/PCI) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">101 (3.8)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">240</p></td>
<td class="Botrule Lrule" align="center"><p class="First">101 (3.9)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">195</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Major leg amputation </p></td>
<td class="Botrule Lrule" align="center"><p class="First">15 (0.6)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">28</p></td>
<td class="Botrule Lrule" align="center"><p class="First">9 (0.3)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">28</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Leg revascularization </p></td>
<td class="Botrule Lrule" align="center"><p class="First">57 (2.2)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">92</p></td>
<td class="Botrule Lrule" align="center"><p class="First">71 (2.7)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">115</p></td>
</tr>
</tbody>
</table>
<p>CABG = coronary artery bypass grafting; PCI = percutaneous intervention </p>
<p><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span><br></span></span>Dose-related <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> occurs when pioglitazone is used alone or in combination with other antidiabetic medications. The mechanism of <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> is unclear but probably involves a combination of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> and fat accumulation. </p>
<p><span class="Bold">Tables 10</span>, <span class="Bold">11</span>, and<span class="Bold"> 12</span> summarize the changes in body weight with pioglitazone and placebo in the 16 to 26 week randomized, double-blind monotherapy and 16 to 24 week combination add-on therapy trials, the PROactive trial, and the 24-week pioglitazone and metformin hydrochloride trial.</p>
<table width="100%">
<caption><span>Table 10: Weight Changes (kg) From Baseline During Randomized, Double-Blind Clinical Trials</span></caption>
<col width="24%">
<col width="12%">
<col width="17%">
<col width="16%">
<col width="16%">
<col width="16%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" colspan="2" rowspan="2"></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Control Group (Placebo)</span></p></td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold">Pioglitazone </span></p>
<p><span class="Bold">15 mg</span></p>
</td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Pioglitazone<br> 30 mg</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Pioglitazone </span></p>
<p><span class="Bold">45 mg</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">Median<br>(25<span class="Sup">th</span>, 75<span class="Sup">th</span> percentile) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">Median <br>(25<span class="Sup">th</span>, 75<span class="Sup">th</span> percentile) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">Median <br>(25<span class="Sup">th</span>, 75<span class="Sup">th</span> percentile) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Median <br>(25<span class="Sup">th</span>, 75<span class="Sup">th</span> percentile) </p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Monotherapy (16 to 26 weeks)</span></p></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center">
<p class="First">-1.4 (-2.7, 0.0)</p>
<p>N = 256</p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First">0.9 (-0.5, 3.4)</p>
<p>N = 79</p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First">1.0 (-0.9, 3.4)</p>
<p>N = 188</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">2.6 (0.2, 5.4)</p>
<p>N = 79</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="3"><p class="First"><span class="Bold">Combination Therapy (16 to 24 weeks)</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">Sulfonylurea</p></td>
<td class="Botrule Lrule" align="center">
<p class="First">-0.5 (-1.8, 0.7)</p>
<p>N = 187</p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First">2.0 (0.2, 3.2)</p>
<p>N = 183</p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First">3.1 (1.1, 5.4)</p>
<p>N = 528</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">4.1 (1.8, 7.3)</p>
<p>N = 333</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">Metformin</p></td>
<td class="Botrule Lrule" align="center">
<p class="First">-1.4 (-3.2, 0.3) </p>
<p>N = 160</p>
</td>
<td class="Botrule Lrule" align="center"><p class="First">N/A</p></td>
<td class="Botrule Lrule" align="center">
<p class="First">0.9 (-1.3, 3.2) </p>
<p>N = 567</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">1.8 (-0.9, 5.0)</p>
<p>N = 407</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"><p class="First">Insulin</p></td>
<td class="Botrule Lrule" align="center">
<p class="First">0.2 (-1.4, 1.4) </p>
<p>N = 182</p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First">2.3 (0.5, 4.3)</p>
<p>N = 190</p>
</td>
<td class="Botrule Lrule" align="center"><p class="First">3.3 (0.9, 6.3)<br> N = 522</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">4.1 (1.4, 6.8)</p>
<p>N = 338</p>
</td>
</tr>
</tbody>
</table>
<table width="100%">
<caption><span>Table 11: Median Change in Body Weight in Patients Treated With Pioglitazone Versus Patients Treated With Placebo During the Double-Blind Treatment Period in the PROactive Trial</span></caption>
<col width="39%">
<col width="22%">
<col width="22%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" rowspan="2"></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Pioglitazone</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">
<p class="First">Median </p>
<p>(25<span class="Sup">th</span>, 75<span class="Sup">th</span> percentile)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">Median </p>
<p>(25<span class="Sup">th</span>, 75<span class="Sup">th</span> percentile)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Change from baseline to final visit (kg) </p></td>
<td class="Botrule Lrule" align="center">
<p class="First">-0.5 (-3.3, 2.0)</p>
<p>N = 2581</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">+3.6 (0.0, 7.5)</p>
<p>N = 2560</p>
</td>
</tr>
</tbody>
</table>
<p>Note: Median exposure for both Pioglitazone and Placebo was 2.7 years.</p>
<table width="100%">
<caption><span>Table 12: Weight Changes (kg) from Baseline During Double-Blind Clinical Trial with Pioglitazone and Metformin Hydrochloride Tablets in Patients with Inadequate Glycemic Control on Diet and Exercise</span></caption>
<col width="27%">
<col width="38%">
<col width="17%">
<col width="17%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Pioglitazone and Metformin Hydrochloride Tablets<br>15/850 mg<br>Twice Daily </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Pioglitazone</span></p>
<p><span class="Bold">15 mg</span></p>
<p><span class="Bold">Twice Daily</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Metformin</span></p>
<p><span class="Bold">850 mg</span></p>
<p><span class="Bold">Twice Daily</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">Median</p>
<p>(25<span class="Sup">th</span> , 75<span class="Sup">th</span> percentile) </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">Median</p>
<p>(25<span class="Sup">th</span> , 75<span class="Sup">th</span> percentile) </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">Median</p>
<p>(25<span class="Sup">th</span> , 75<span class="Sup">th</span> percentile) </p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule">
<p class="First">Change from baseline to final visit (kg) </p>
<p></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">1.00 (-1.0, 3.0)</p>
<p>N = 198 </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">1.35 (-0.7, 4.1)</p>
<p>N = 178 </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">-1.00 (-2.6, 0.4)</p>
<p>N = 203 </p>
</td>
</tr>
</tbody>
</table>
<p>Note: Trial duration of 24 weeks.</p>
<p><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span><br></span></span><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> induced from taking pioglitazone is reversible when pioglitazone is discontinued. The <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> usually does not require hospitalization unless there is coexisting <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</p>
<p>In the 24-week pioglitazone and metformin hydrochloride tabletstrial, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> was reported in 3.0% of patients in the pioglitazone and metformin hydrochloride tabletsgroup, 4.2% in the pioglitazone monotherapy group, and 1.4% in the metformin monotherapy group.</p>
<p>A summary of the frequency and types of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> adverse events occurring in clinical investigations of pioglitazone is provided in <span class="Bold">Table 13</span>.</p>
<table width="100%">
<caption><span>Table 13: Adverse Events of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> in Patients Treated With Pioglitazone</span></caption>
<col width="34%">
<col width="14%">
<col width="12%">
<col width="13%">
<col width="13%">
<col width="13%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" colspan="2" rowspan="2"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4"><p class="First"><span class="Bold">Number (%) of Patients</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Pioglitazone <br>15 mg</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Pioglitazone <br>30 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Pioglitazone <br>45 mg</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" colspan="2">
<p class="First"><span class="Bold">Monotherapy </span></p>
<p><span class="Bold">(16 to 26 weeks)</span></p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First">3 (1.2%) </p>
<p>N = 259</p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First">2 (2.5%)</p>
<p>N = 81</p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First">13 (4.7%)</p>
<p>N = 275</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">11 (6.5%)</p>
<p>N = 169</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="3"><p class="First"><span class="Bold">Combined Therapy<br> (16 to 24 weeks)</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">Sulfonylurea</p></td>
<td class="Botrule Lrule" align="center">
<p class="First">4 (2.1%) </p>
<p>N = 187</p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First">3 (1.6%)</p>
<p>N = 184</p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First">61 (11.3%)</p>
<p>N = 540</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">81 (23.1%)</p>
<p>N = 351</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">Metformin</p></td>
<td class="Botrule Lrule" align="center">
<p class="First">4 (2.5%) </p>
<p>N = 160</p>
</td>
<td class="Botrule Lrule" align="center"><p class="First">N/A</p></td>
<td class="Botrule Lrule" align="center">
<p class="First">34 (5.9%)</p>
<p>N = 579</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">58 (13.9%)</p>
<p>N = 416</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"><p class="First">Insulin</p></td>
<td class="Botrule Lrule" align="center">
<p class="First">13 (7.0%)</p>
<p>N = 187</p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First">24 (12.6%)</p>
<p>N = 191</p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First">109 (20.5%)</p>
<p>N = 533</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">90 (26.1%)</p>
<p>N = 345</p>
</td>
</tr>
</tbody>
</table>
<p>Note: The preferred terms of <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span>, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">pitting edema</span> and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> were combined to form the aggregate term of “edema.?</p>
<table width="100%">
<caption><span>Table 14: Adverse Events of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> in Patients in the PROactive Trial</span></caption>
<col width="14%">
<col width="14%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Number (%) of Patients</span></p></td></tr>
<tr>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Placebo</span></p>
<p>N = 2633</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">Pioglitazone</span></p>
<p>N = 2605</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"><p class="First">419 (15.9%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">712 (27.3%)</p></td>
</tr>
</tbody>
</table>
<p>Note: The preferred terms of <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span>, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">pitting edema</span>, and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> were combined to form the aggregate term of “edema.?</p>
<p><span class="Bold"><span class="Underline">Hepatic Effects<br></span></span>There has been no evidence of pioglitazone-induced hepatotoxicity in the pioglitazone controlled clinical trial database to date. One randomized, double-blind, three-year trial comparing pioglitazone to glyburide as add-on to metformin and insulin therapy was specifically designed to evaluate the incidence of serum ALT elevation to greater than three times the upper limit of the reference range, measured every eight weeks for the first 48 weeks of the trial then every 12 weeks thereafter. A total of 3/1051 (0.3%) patients treated with pioglitazone and 9/1046 (0.9%) patients treated with glyburide developed ALT values greater than three times the upper limit of the reference range. None of the patients treated with pioglitazone in the pioglitazone controlled clinical trial database to date have had a serum ALT greater than three times the upper limit of the reference range and a corresponding total bilirubin greater than two times the upper limit of the reference range, a combination predictive of the potential for severe drug-induced <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>. </p>
<p><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span><br></span></span>In the pioglitazone clinical trials, adverse events of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> were reported based on clinical judgment of the investigators and did not require confirmation with fingerstick glucose testing. </p>
<p>In the 16 week add-on to sulfonylurea trial, the incidence of reported <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 3.7% with pioglitazone 30 mg and 0.5% with placebo. In the 16 week add-on to insulin trial, the incidence of reported <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 7.9% with pioglitazone 15 mg, 15.4% with pioglitazone 30 mg, and 4.8% with placebo. </p>
<p>The incidence of reported <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was higher with pioglitazone 45 mg compared to pioglitazone 30 mg in both the 24 week add-on to sulfonylurea trial (15.7% versus 13.4%) and in the 24 week add-on to insulin trial (47.8% versus 43.5%). </p>
<p>Three patients in these four trials were hospitalized due to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. All three patients were receiving pioglitazone 30 mg (0.9%) in the 24 week add-on to insulin trial. An additional 14 patients reported severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (defined as causing considerable interference with patient’s usual activities) that did not require hospitalization. These patients were receiving pioglitazone 45 mg in combination with sulfonylurea (n = 2) or pioglitazone 30 mg or 45 mg in combination with insulin (n = 12). </p>
<p><span class="Bold"><span class="Underline">Urinary Bladder Tumors</span></span></p>
<p>Tumors were observed in the urinary bladder of male rats in the two-year carcinogenicity study [<span class="Italics">see Nonclinical Toxicology (<a href="#i4i_carcinogenesis_mutagenesis_fertility_id_83434e02-87f4-48d8-b22d-9553b9c8bd59">13.1</a>)</span>]. In two 3 year trials in which pioglitazone was compared to placebo or glyburide, there were 16/3656 (0.44%) reports of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> in patients taking pioglitazone compared to 5/3679 (0.14%) in patients not taking pioglitazone. After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>, there were six (0.16%) cases on pioglitazone and two (0.05%) cases on placebo. There are too few events of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> to establish causality. </p>
<p><span class="Bold">Metformin hydrochloride</span></p>
<p>In a double-blind clinical study of metformin in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, a total of 141 patients received metformin therapy (up to 2550 mg per day) and 145 patients received placebo. Adverse reactions reported in greater than 5% of the metformin patients, and that were more common in metformin than placebo-treated patients, are listed in <span class="Bold">Table 15</span>. In this trial, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> led to discontinuation of study medication in 6% of patients treated with metformin.</p>
<table width="100%">
<caption><span>Table 15: Most Common Adverse Reactions (&gt; 5.0%) in a Placebo-Controlled Clinical Study of Metformin Monotherapy<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col width="24%">
<col width="27%">
<col width="12%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Reactions that were more common in metformin than placebo-treated patients.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" rowspan="2"><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold">Metformin Monotherapy</span></p>
<p><span class="Bold">(n = 141)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold"> (n = 145)</span></p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">% of Patients</span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">53.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">25.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">12.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">9.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Indigestion</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">7.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal Discomfort</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">6.4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.8</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">5.7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.8</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0474b762-6d28-4059-ad8f-2cab74db7461"></a><a name="section-6.2"></a><p></p>
<h2><span class="Bold">Laboratory Abnormalities </span></h2>
<p class="First"><span class="Bold">Hematologic Effects<br></span>Pioglitazone may cause decreases in hemoglobin and hematocrit. In placebo-controlled monotherapy trials, mean hemoglobin values declined by 2% to 4% in patients treated with pioglitazone compared with a mean change in hemoglobin of -1% to +1% in placebo-treated patients. These changes primarily occurred within the first four to 12 weeks of therapy and remained relatively constant thereafter. These changes may be related to increased plasma volume associated with pioglitazone therapy and are not likely to be associated with any clinically significant hematologic effects. </p>
<p><span class="Bold">Vitamin B<span class="Sub">12</span> Concentrations<br></span>Metformin may lower serum vitamin B<span class="Sub">12</span> concentrations. Measurement of hematologic parameters on an annual basis is advised in patients on pioglitazone and metformin hydrochloride tablets and any apparent abnormalities should be appropriately investigated and managed [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_54ed08aa-475b-4b54-93ba-96f92faa4106">5.14</a>)</span>]. </p>
<p><span class="Bold">Creatine Phosphokinase<br></span>During protocol-specified measurement of serum creatine phosphokinase (CPK) in pioglitazone clinical trials, an isolated elevation in CPK to greater than 10 times the upper limit of the reference range was noted in nine (0.2%) patients treated with pioglitazone (values of 2150 to 11400 IU/L) and in no comparator-treated patients. Six of these nine patients continued to receive pioglitazone, two patients were noted to have the CPK elevation on the last day of dosing, and one patient discontinued pioglitazone due to the elevation. These elevations resolved without any apparent clinical sequelae. The relationship of these events to pioglitazone therapy is unknown. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_42cedc86-541a-49e0-a241-bb432cb982bc"></a><a name="section-6.3"></a><p></p>
<h2>6.2 Postmarketing Experience </h2>
<p class="First"><span class="Bold">Pioglitazone </span></p>
<p>The following adverse reactions have been identified during post-approval use of pioglitazone. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </p>
<dl>
<dt>•</dt>
<dd>New onset or worsening <span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">diabetic macular edema</span> with decreased visual acuity [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_dc99b8df-1fd4-409c-922c-c9c03305bbcd">5.8</a>)</span>]. </dd>
<dt>•</dt>
<dd>Fatal and nonfatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_9cd1f475-f0cc-4e5d-9581-d9d82e8ca411">5.5</a>)</span>]. </dd>
</dl>
<p>Postmarketing reports of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> have been reported in patients treated with pioglitazone, both with and without previously known heart disease and both with and without concomitant insulin administration. </p>
<p>In postmarketing experience, there have been reports of unusually rapid increases in weight and increases in excess of that generally observed in clinical trials. Patients who experience such increases should be assessed for fluid accumulation and volume-related events such as excessive <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> [<span class="Italics">see <a href="#i4i_boxed_warning_id_3f104af2-1fd3-45c7-b374-dea16ef6decd">Boxed Warning</a> and Warnings and Precautions (<a href="#i4i_section_id_8177ec74-2b3c-4e22-8fca-6355648bc970">5.1</a>)</span>]. </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_e4fe1c67-dbc5-4b48-bb4c-baf5c9c146e8"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d3254fd0-d618-417d-8d53-4556a0126bf8"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Strong CYP2C8 Inhibitors </h2>
<p class="First">An inhibitor of CYP2C8 (e.g., gemfibrozil) significantly increases the exposure (area under the serum concentration-time curve or AUC) and half-life (t<span class="Sub">1/2</span>) of pioglitazone. Therefore, the maximum recommended dose of pioglitazone is 15 mg daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_a213629f-661b-4969-9f42-971871d9844e">2.3</a>) and Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_6b289b9c-e13b-4de0-9850-a6a18dc42bad">12.3</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0b390350-8d95-4454-b0c8-8bfc9d238461"></a><a name="section-7.2"></a><p></p>
<h2>7.2 CYP2C8 Inducers </h2>
<p class="First">An inducer of CYP2C8 (e.g., rifampin) may significantly decrease the exposure (AUC) of pioglitazone. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with pioglitazone, changes in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> treatment may be needed based on clinical response without exceeding the maximum recommended daily dose of 45 mg for pioglitazone [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_6b289b9c-e13b-4de0-9850-a6a18dc42bad">12.3</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3f319930-8c5f-469a-87b8-76ac5b751b00"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Carbonic Anhydrase Inhibitors </h2>
<p class="First">Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) frequently decrease serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> and induce non-<span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span>, hyperchloremic <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>. Concomitant use of these drugs may induce <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>. Use these drugs with caution in patients treated with metformin, as the risk of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> may increase. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a155d100-3328-4c75-8aec-00600b51f4ee"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Cationic Drugs </h2>
<p class="First">Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. Although such interactions remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of pioglitazone and metformin hydrochloride tablets and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_6b289b9c-e13b-4de0-9850-a6a18dc42bad">12.3</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d7c5b005-9081-4e22-9694-b7e7e181d826"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Drugs Affecting Glycemic Control </h2>
<p class="First">Certain drugs tend to produce <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. When such drugs are administered to a patient receiving pioglitazone and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving pioglitazone and metformin hydrochloride tablets, the patient should be observed closely for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_483efd9d-f923-4433-af14-e61c4574c1f8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_1f238f87-2a92-40d2-a413-09661c872343"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Teratogenic Effects</span></p>
<p>Pregnancy Category C</p>
<p>There are no adequate and well-controlled studies of pioglitazone and metformin hydrochloride tablets or its individual components in pregnant women. Animal studies using pioglitazone show increased rates of post-implantation loss, delayed development, reduced fetal weights, and delayed parturition at doses 10 to 40 times the maximum recommended human dose. Pioglitazone and metformin hydrochloride tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
<p><span class="Bold">Pioglitazone </span></p>
<p><span class="Bold"><span class="Italics">Clinical Considerations</span><br></span>Abnormal blood glucose concentrations during pregnancy are associated with a higher incidence of congenital anomalies, as well as increased neonatal morbidity and mortality. Most experts recommend the use of insulin during pregnancy to maintain blood glucose concentrations as close to normal as possible for patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. </p>
<p><span class="Bold"><span class="Italics">Animal Data</span><br></span>In animal reproductive studies, pregnant rats and rabbits received pioglitazone at doses up to approximately 17 (rat) and 40 (rabbit) times the maximum recommended human oral dose (MRHD) based on body surface area (mg/m<span class="Sup">2</span>); no <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed. Increases in embryotoxicity (increased postimplantation losses, delayed development, reduced fetal weights, and delayed parturition) occurred in rats that received oral doses approximately 10 or more times the MRHD (mg/m<span class="Sup">2</span> basis). No functional or behavioral toxicity was observed in rat offspring. When pregnant rats received pioglitazone during late gestation and lactation, delayed postnatal development, attributed to decreased body weight, occurred in rat offspring at oral maternal doses approximately 2 or more times the MRHD (mg/m<span class="Sup">2</span> basis). In rabbits, embryotoxicity occurred at oral doses approximately 40 times the MRHD (mg/m<span class="Sup">2</span> basis). </p>
<p><span class="Bold">Metformin hydrochloride</span></p>
<p>Metformin was not teratogenic in rats and rabbits at doses up to 600 mg/kg/day. This represents an exposure of about two and six times a human daily dose of 2000 mg based on body surface area comparisons for rats and rabbits, respectively. However, because animal reproduction studies are not always predictive of human response, metformin should not be used during pregnancy unless clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_407e0b7e-f308-4aa7-a4f3-cdfb29c0a3df"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">The effect of pioglitazone and metformin hydrochloride tablets on labor and delivery in humans is not known. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_1a358896-99c4-48c7-a7c5-e8472eb9cd74"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">No studies have been conducted with the combined components of pioglitazone and metformin hydrochloride tablets. In studies performed with the individual components, both pioglitazone and metformin are secreted in the milk of lactating rats. It is not known whether pioglitazone and/or metformin are secreted in human milk. Because many drugs are excreted in human milk, and because of the potential for pioglitazone and metformin hydrochloride tablets to cause serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue pioglitazone and metformin hydrochloride tablets, taking into account the importance of pioglitazone and metformin hydrochloride tablets to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_ed0239f2-e5ad-48a2-a3f6-8a3714154972"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of pioglitazone and metformin hydrochloride tablets in pediatric patients have not been established. </p>
<p>Pioglitazone and metformin hydrochloride tablets are not recommended for use in pediatric patients based on adverse effects observed in adults, including <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, and urinary bladder tumors [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_8177ec74-2b3c-4e22-8fca-6355648bc970">5.1</a>, <a href="#i4i_section_id_249a319e-1d6f-459b-bec4-278bcb091e7a">5.3</a>, <a href="#_RefID645DAC44E5B448C7A66684319DD53139">5.6</a>, <a href="#i4i_section_id_7e61b83e-e339-4a5d-be77-229a84c0be0d">5.7</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_3c90a195-8623-49a0-a501-477966029998"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First"><span class="Bold">Pioglitazone </span></p>
<p>A total of 92 patients (15.2%) treated with pioglitazone in the three pooled 16 to 26 week double-blind, placebo-controlled, monotherapy trials were ≥ 65 years old and two patients (0.3%) were ≥ 75 years old. In the two pooled 16 to 24 week add-on to sulfonylurea trials, 201 patients (18.7%) treated with pioglitazone were ≥ 65 years old and 19 (1.8%) were ≥ 75 years old. In the two pooled 16 to 24 week add-on to metformin trials, 155 patients (15.5%) treated with pioglitazone were ≥ 65 years old and 19 (1.9%) were ≥ 75 years old. In the two pooled 16 to 24 week add-on to insulin trials, 272 patients (25.4%) treated with pioglitazone were ≥ 65 years old and 22 (2.1%) were ≥ 75 years old. </p>
<p>In PROactive Trial, 1068 patients (41.0%) treated with pioglitazone were ≥ 65 years old and 42 (1.6%) were ≥ 75 years old. </p>
<p>In pharmacokinetic studies with pioglitazone, no significant differences were observed in pharmacokinetic parameters between elderly and younger patients [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_6b289b9c-e13b-4de0-9850-a6a18dc42bad">12.3</a>)].</span><br><br>Although clinical experiences have not identified differences in effectiveness and safety between the elderly (≥ 65 years) and younger patients, these conclusions are limited by small sample sizes for patients ≥ 75 years old. </p>
<p><span class="Bold">Metformin hydrochloride</span></p>
<p>Controlled clinical studies of metformin did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients, although other reported clinical experience has not identified differences in responses between the elderly and young patients. Metformin is known to be substantially excreted by the kidney and because the risk of serious adverse reactions to the drug is greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, pioglitazone and metformin hydrochloride tablets should only be used in patients with normal renal function [<span class="Italics">see Contraindications (<a href="#i4i_contraindications_id_6c47db78-3491-47bd-9c0c-26d9274bba72">4</a>), Warnings and Precautions (<a href="#i4i_section_id_75c7c85e-1104-4b47-ac01-1d2707206413">5.2</a>) and Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_6b289b9c-e13b-4de0-9850-a6a18dc42bad">12.3</a>)</span>]. Because aging is associated with reduced renal function, pioglitazone and metformin hydrochloride tablets should be used with caution as age increases. Care should be taken in dose selection and should be based on careful and regular monitoring of renal function. Generally, elderly patients should not be titrated to the maximum dose of pioglitazone and metformin hydrochloride tablets [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_75c7c85e-1104-4b47-ac01-1d2707206413">5.2</a>) and Dosage and Administration (<a href="#i4i_dosage_admin_id_1c91f6d5-c9de-422b-bc2e-73af14091222">2</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_4b07a125-8140-467a-8ea1-b1e797d04390"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"><span class="Italics">Pioglitazone </span></p>
<p>During controlled clinical trials, one case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with pioglitazone was reported. A male patient took 120 mg per day for four days, then 180 mg per day for seven days. The patient denied any clinical symptoms during this period. </p>
<p>In the event of overdosage, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms. </p>
<p><span class="Italics">Metformin hydrochloride </span></p>
<p><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> of metformin hydrochloride has occurred, including ingestion of amounts greater than 50 grams. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> was reported in approximately 10% of cases, but no causal association with metformin hydrochloride has been established. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> has been reported in approximately 32% of metformin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> cases [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_75c7c85e-1104-4b47-ac01-1d2707206413">5.2</a>)</span>]. Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated metformin from patients in whom metformin overdosage is suspected. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_7347e474-7909-4311-a306-3e510fc46116"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Pioglitazone and metformin hydrochloride tablets USP contain two oral antidiabetic medications used in the management of type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>: pioglitazone hydrochloride, USP and metformin hydrochloride, USP. </p>
<p>Pioglitazone [(±)-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy]phenyl]methyl]-2,4-] thiazolidinedione monohydrochloride contains one asymmetric carbon, and the compound is synthesized and used as the racemic mixture. The two enantiomers of pioglitazone interconvert<span class="Italics"> in vivo</span>. No differences were found in the pharmacologic activity between the two enantiomers. The structural formula is as shown:</p>
<div class="Figure">
<a name="id1628"></a><img alt="structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7dbc36d-3c84-488e-9b72-0593b5ed53a0&amp;name=image-01.jpg">
</div>
<p>C<span class="Sub">19</span>H<span class="Sub">20</span>N<span class="Sub">2</span>O<span class="Sub">3</span>S•HCl            M.W. 392.90</p>
<p>Pioglitazone hydrochloride, USP is an odorless white crystalline powder. It is soluble in <span class="Italics">N,N</span>-dimethylformamide, slightly soluble in anhydrous ethanol, very slightly soluble in acetone and acetonitrile, practically insoluble in water, and insoluble in ether. </p>
<p>Metformin hydrochloride, USP (Imidodicarbonimidic diamide, <span class="Italics">N,N</span>-dimethyl-, monohydrochloride) is a white crystalline powder. Metformin hydrochloride is freely soluble in water, slightly soluble in alcohol, practically insoluble in acetone and in methylene chloride. The pKa of metformin is 12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68. The structural formula is as shown:</p>
<div class="Figure">
<a name="id1639"></a><img alt="structual formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7dbc36d-3c84-488e-9b72-0593b5ed53a0&amp;name=image-02.jpg">
</div>
<p>C<span class="Sub">4</span>H<span class="Sub">11</span>N<span class="Sub">5</span>•HCl           M.W. 165.62</p>
<p>Pioglitazone and metformin hydrochloride tablets USP are available as a tablet for oral administration containing 15 mg pioglitazone hydrochloride, USP (as the base) with 500 mg metformin hydrochloride, USP (15 mg/500 mg) or 15 mg pioglitazone hydrochloride, USP (as the base) with 850 mg metformin hydrochloride, USP (15 mg/850 mg) formulated with the following excipients: colloidal silicon dioxide, cornstarch, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, povidone, talc, and titanium dioxide.</p>
<p><span class="Italics">The USP Dissolution Test is pending.</span></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_57f1eded-da8b-4c77-8694-50be4c635cd7"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_0fc01512-ff99-4792-86c1-0683db048ce5"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Pioglitazone and metformin hydrochloride tablets combine two antidiabetic medications with different mechanisms of action to improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>: pioglitazone, a thiazolidinedione, and metformin hydrochloride, a biguanide. Thiazolidinediones are insulin-sensitizing agents that act primarily by enhancing peripheral glucose utilization, whereas biguanides act primarily by decreasing endogenous hepatic glucose production. </p>
<p><span class="Bold">Pioglitazone </span></p>
<p>Pioglitazone is a thiazolidinedione that depends on the presence of insulin for its mechanism of action. Pioglitazone decreases <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span> in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is not an insulin secretagogue. Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPARγ). PPAR receptors are found in tissues important for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPARγ nuclear receptors modulates the transcription of a number of insulin responsive genes involved in the control of glucose and lipid metabolism. </p>
<p>In animal models of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, pioglitazone reduces the <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4307509" conceptname="Hyperinsulinism">hyperinsulinemia</span>, and <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> characteristic of insulin-resistant states such as type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. The metabolic changes produced by pioglitazone result in increased responsiveness of insulin-dependent tissues and are observed in numerous animal models of <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span>. </p>
<p>Because pioglitazone enhances the effects of circulating insulin (by decreasing <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span>), it does not lower blood glucose in animal models that lack endogenous insulin. </p>
<p><span class="Bold">Metformin hydrochloride </span></p>
<p>Metformin hydrochloride improves glucose tolerance in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Metformin does not produce <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in either patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or healthy subjects [except in specific circumstances, <span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_d84d70f3-d85d-4535-b791-a08e83467b25">5.4</a>)</span>] and does not cause <span class="product-label-link" type="condition" conceptid="4307509" conceptname="Hyperinsulinism">hyperinsulinemia</span>. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease. </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_05d2247e-edff-48ba-b7e0-138dc5f9543d"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><span class="Bold">Pioglitazone </span></p>
<p>Clinical studies demonstrate that pioglitazone improves insulin sensitivity in insulin-resistant patients. Pioglitazone enhances cellular responsiveness to insulin, increases insulin-dependent glucose disposal and improves hepatic sensitivity to insulin. In patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, the decreased <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span> produced by pioglitazone results in lower plasma glucose concentrations, lower plasma insulin concentrations, and lower HbA1c values. In controlled clinical trials, pioglitazone had an additive effect on glycemic control when used in combination with a sulfonylurea, metformin, or insulin [<span class="Italics">see Clinical Studies (<a href="#i4i_clinical_studies_id_4f919de5-f3dd-41b3-960f-3dda207644eb">14</a>)</span>]. </p>
<p>Patients with lipid abnormalities were included in clinical trials with pioglitazone. Overall, patients treated with pioglitazone had mean decreases in serum triglycerides, mean increases in HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and no consistent mean changes in LDL and total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. There is no conclusive evidence of macrovascular benefit with pioglitazone or any other antidiabetic medication [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_5491d17a-c806-442f-96d4-afec633c2ce7">5.15</a>) and Adverse Reactions (<a href="#i4i_section_id_ea958dfc-0d84-4561-965f-87c6661b24ed">6.1</a>)</span>]. </p>
<p>In a 26 week, placebo-controlled, dose-ranging monotherapy study, mean serum triglycerides decreased in the 15 mg, 30 mg, and 45 mg pioglitazone dose groups compared to a mean increase in the placebo group. Mean HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> increased to a greater extent in patients treated with pioglitazone than in the placebo-treated patients. There were no consistent differences for LDL and total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in patients treated with pioglitazone compared to placebo (see <a href="#Table16">Table 16</a>).</p>
<p>Table <a href="#">16</a>: Lipids in a 26 Week Placebo-Controlled Monotherapy Dose-Ranging Study</p>
<table width="100%">
<col width="46%">
<col width="10%">
<col width="14%">
<col width="14%">
<col width="14%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Adjusted for baseline, pooled center, and pooled center by treatment interaction</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>p &lt; 0.05 versus placebo</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold">Pioglitazone </span></p>
<p><span class="Bold">15 mg</span></p>
<p><span class="Bold">Once Daily</span></p>
</td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold">Pioglitazone </span></p>
<p><span class="Bold">30 mg</span></p>
<p><span class="Bold">Once Daily</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Pioglitazone</span></p>
<p><span class="Bold">45 mg</span></p>
<p><span class="Bold">Once Daily</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Triglycerides (mg/dL) </span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">N = 79</p></td>
<td class="Botrule Lrule" align="center"><p class="First">N = 79</p></td>
<td class="Botrule Lrule" align="center"><p class="First">N = 84</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">N = 77</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Baseline (mean) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">263</p></td>
<td class="Botrule Lrule" align="center"><p class="First">284</p></td>
<td class="Botrule Lrule" align="center"><p class="First">261</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">260</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Percent change from baseline (adjusted mean<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">4.8%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-9.0%<a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">-9.6%<a href="#footnote-3" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-9.3%<a href="#footnote-3" class="Sup">†</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (mg/dL) </span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">N = 79</p></td>
<td class="Botrule Lrule" align="center"><p class="First">N = 79</p></td>
<td class="Botrule Lrule" align="center"><p class="First">N = 83</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">N = 77</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Baseline (mean) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">42</p></td>
<td class="Botrule Lrule" align="center"><p class="First">40</p></td>
<td class="Botrule Lrule" align="center"><p class="First">41</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">41</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Percent change from baseline (adjusted mean)<a href="#footnote-2" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">8.1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">14.1%<a href="#footnote-3" class="Sup">†</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">12.2%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">19.1%<a href="#footnote-3" class="Sup">†</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (mg/dL) </span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">N = 65</p></td>
<td class="Botrule Lrule" align="center"><p class="First">N = 63</p></td>
<td class="Botrule Lrule" align="center"><p class="First">N = 74</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">N = 62</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Baseline (mean) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">139</p></td>
<td class="Botrule Lrule" align="center"><p class="First">132</p></td>
<td class="Botrule Lrule" align="center"><p class="First">136</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">127</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Percent change from baseline (adjusted mean)<a href="#footnote-2" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">4.8%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">7.2%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">5.2%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6.0%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (mg/dL) </span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">N = 79</p></td>
<td class="Botrule Lrule" align="center"><p class="First">N = 79</p></td>
<td class="Botrule Lrule" align="center"><p class="First">N = 84</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">N = 77</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Baseline (mean) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">225</p></td>
<td class="Botrule Lrule" align="center"><p class="First">220</p></td>
<td class="Botrule Lrule" align="center"><p class="First">223</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">214</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Percent change from baseline (adjusted mean)<a href="#footnote-2" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">4.4%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">4.6%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">3.3%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6.4%</p></td>
</tr>
</tbody>
</table>
<p>In the two other monotherapy studies (16 weeks and 24 weeks) and in combination therapy studies with metformin (16 weeks and 24 weeks), the results were generally consistent with the data above. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_6b289b9c-e13b-4de0-9850-a6a18dc42bad"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold">Absorption </span></p>
<p><span class="Bold"><span class="Italics">Pioglitazone and Metformin Hydrochloride Tablets</span></span></p>
<p>In bioequivalence studies of pioglitazone and metformin hydrochloride tablets 15 mg/500 mg and 15 mg/850 mg, the area under the curve (AUC) and maximum concentration (C<span class="Sub">max</span>) of both the pioglitazone and the metformin component following a single dose of the combination tablet were bioequivalent to ACTOS<span class="Sup">®</span> 15 mg concomitantly administered with GLUCOPHAGE<span class="Sup">®</span> (500 mg or 850 mg respectively) tablets under fasted conditions in healthy subjects. </p>
<p>Administration of pioglitazone and metformin hydrochloride tablets 15 mg/850 mg with food resulted in no change in overall exposure of pioglitazone. With metformin there was no change in AUC; however, mean peak serum concentration of metformin was decreased by 28% when administered with food. A delayed time to peak serum concentration was observed for both components (1.9 hours for pioglitazone and 0.8 hours for metformin) under fed conditions. These changes are not likely to be clinically significant.</p>
<p><span class="Bold"><span class="Italics">Pioglitazone </span></span></p>
<p>Following once-daily administration of pioglitazone, steady-state serum concentrations of both pioglitazone and its major active metabolites, M-III (keto derivative of pioglitazone) and M-IV (hydroxyl derivative of pioglitazone), are achieved within seven days. At steady-state, M-III and M-IV reach serum concentrations equal to or greater than that of pioglitazone. At steady-state, in both healthy volunteers and patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, pioglitazone comprises approximately 30% to 50% of the peak total pioglitazone serum concentrations (pioglitazone plus active metabolites) and 20% to 25% of the total AUC. </p>
<p>C<span class="Sub">max</span>, AUC, and trough serum concentrations (C<span class="Sub">min</span>) for pioglitazone and M-III and M-IV, increased proportionally with administered doses of 15 mg and 30 mg per day. </p>
<p>Following oral administration of pioglitazone, T<span class="Sub">max</span> of pioglitazone was within two hours. Food delays the T<span class="Sub">max </span>to three to four hours, but does not alter the extent of absorption (AUC). </p>
<p><span class="Bold"><span class="Italics">Metformin hydrochloride </span></span></p>
<p>The absolute bioavailability of a 500 mg metformin tablet given under fasting conditions is approximately 50% to 60%. Studies using single oral doses of metformin tablets of 500 mg to 1500 mg, and 850 mg to 2550 mg, indicate that there is a lack of dose proportionality with increasing doses, which is due to decreased absorption rather than an alteration in elimination. At usual clinical doses and dosing schedules of metformin, steady-state plasma concentrations of metformin are reached within 24 to 48 hours and are generally &lt; 1 mcg/mL. During controlled clinical trials, maximum metformin plasma levels did not exceed 5 mcg/mL, even at maximum doses.<br><br>Food decreases the rate and extent of metformin absorption, as shown by a 40% lower mean C<span class="Sub">max</span>, a 25% lower AUC, and a 35 minute prolongation of T<span class="Sub">max</span> following administration of a single 850 mg tablet of metformin with food, compared to the same tablet strength administered fasting. The clinical relevance of these decreases is unknown. </p>
<p><span class="Bold">Distribution </span></p>
<p><span class="Bold"><span class="Italics">Pioglitazone</span></span></p>
<p>The mean apparent volume of distribution (Vd/F) of pioglitazone following single-dose administration is 0.63 ± 0.41 (mean ± SD) L/kg of body weight. Pioglitazone is extensively protein bound (&gt; 99%) in human serum, principally to serum albumin. Pioglitazone also binds to other serum proteins, but with lower affinity. M-III and M-IV are also extensively bound (&gt; 98%) to serum albumin. </p>
<p><span class="Bold"><span class="Italics">Metformin hydrochloride </span></span></p>
<p>The Vd/F of metformin following single oral doses of 850 mg immediate-release metformin averaged 654 ± 358 L. Metformin is negligibly bound to plasma proteins. Metformin partitions into erythrocytes, most likely as a function of time. </p>
<p><span class="Bold">Metabolism </span></p>
<p><span class="Bold"><span class="Italics">Pioglitazone </span></span></p>
<p>Pioglitazone is extensively metabolized by hydroxylation and oxidation; the metabolites also partly convert to glucuronide or sulfate conjugates. Metabolites M-III and M-IV are the major circulating active metabolites in humans.</p>
<p><span class="Italics">In vitro</span> data demonstrate that multiple CYP isoforms are involved in the metabolism of pioglitazone which include CYP2C8 and, to a lesser degree, CYP3A4 with additional contributions from a variety of other isoforms, including the mainly extrahepatic CYP1A1. <span class="Italics">In vivo</span> study of pioglitazone in combination with gemfibrozil, a strong CYP2C8 inhibitor, showed that pioglitazone is a CYP2C8 substrate [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_a213629f-661b-4969-9f42-971871d9844e">2.3</a>) and Drug Interactions (<a href="#i4i_section_id_d3254fd0-d618-417d-8d53-4556a0126bf8">7.1</a>)</span>]. Urinary 6ß-hydroxycortisol/cortisol ratios measured in patients treated with pioglitazone showed that pioglitazone is not a strong CYP3A4 enzyme inducer. </p>
<p><span class="Bold"><span class="Italics">Metformin hydrochloride </span></span></p>
<p>Intravenous single-dose studies in healthy subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) nor biliary excretion. </p>
<p><span class="Bold">Excretion and Elimination </span></p>
<p><span class="Bold"><span class="Italics">Pioglitazone </span></span></p>
<p>Following oral administration, approximately 15% to 30% of the pioglitazone dose is recovered in the urine. Renal elimination of pioglitazone is negligible and the drug is excreted primarily as metabolites and their conjugates. It is presumed that most of the oral dose is excreted into the bile either unchanged or as metabolites and eliminated in the feces. </p>
<p>The mean serum half-life (t<span class="Sub">1/2</span>) of pioglitazone and its metabolites (M-III and M-IV) range from three to seven hours and 16 to 24 hours, respectively. Pioglitazone has an apparent clearance, CL/F, calculated to be five to seven L/hr. </p>
<p><span class="Bold"><span class="Italics">Metformin hydrochloride </span></span></p>
<p>Renal clearance is approximately 3.5 times greater than creatinine clearance (CL<span class="Sub">cr</span>) which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination t<span class="Sub">1/2</span> of approximately 6.2 hours. In blood, the elimination t<span class="Sub">1/2 </span>is approximately 17.6 hours, suggesting that the erythrocyte <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> may be a compartment of distribution. </p>
<p><span class="Bold">Specific Populations </span></p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </span></span></p>
<p><span class="Bold"><span class="Underline">Pioglitazone </span></span></p>
<p>The serum elimination half-life of pioglitazone, M-III and M-IV remains unchanged in patients with moderate (CL<span class="Sub">cr</span> 30 to 50 mL/min) and severe (CL<span class="Sub">cr</span> &lt; 30 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> when compared to subjects with normal renal function. Therefore, no dose adjustment in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is required. </p>
<p><span class="Bold"><span class="Underline">Metformin hydrochloride </span></span></p>
<p>In patients with decreased renal function (based on CL<span class="Sub">cr</span>), the plasma and blood t<span class="Sub">1/2 </span>of metformin is prolonged and the renal clearance is decreased in proportion to the decrease in CL<span class="Sub">cr</span> [<span class="Italics">see Contraindications (<a href="#i4i_contraindications_id_6c47db78-3491-47bd-9c0c-26d9274bba72">4</a>) and Warnings and Precautions (<a href="#i4i_section_id_75c7c85e-1104-4b47-ac01-1d2707206413">5.2</a>)</span>]. Because metformin is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, pioglitazone and metformin hydrochloride tablets are also contraindicated in these patients. </p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </span></span></p>
<p><span class="Bold"><span class="Underline">Pioglitazone </span></span></p>
<p>Compared with healthy controls, subjects with impaired hepatic function (Child-Turcotte-Pugh Grade B/C) have an approximate 45% reduction in pioglitazone and total pioglitazone (pioglitazone, M-III, and M-IV) mean C<span class="Sub">max</span> but no change in the mean AUC values. Therefore, no dose adjustment in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is required. </p>
<p>There are postmarketing reports of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> with pioglitazone and clinical trials have generally excluded patients with serum ALT &gt; 2.5 times the upper limit of the reference range. Use pioglitazone and metformin hydrochloride tablets with caution in patients with liver disease [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_9cd1f475-f0cc-4e5d-9581-d9d82e8ca411">5.5</a>)</span>]. </p>
<p><span class="Bold"><span class="Underline">Metformin hydrochloride </span></span></p>
<p>No pharmacokinetic studies of metformin have been conducted in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Use of metformin in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> has been associated with some cases of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. Pioglitazone and metformin hydrochloride tablets are not recommended in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_9cd1f475-f0cc-4e5d-9581-d9d82e8ca411">5.5</a>)</span>]. </p>
<p><span class="Bold"><span class="Italics">Geriatric Patients </span></span></p>
<p><span class="Bold"><span class="Underline">Pioglitazone </span></span></p>
<p>In healthy elderly subjects, C<span class="Sub">max</span> of pioglitazone was not significantly different, but AUC values were approximately 21% higher than those achieved in younger subjects. The mean t<span class="Sub">1/2 </span>of pioglitazone was also prolonged in elderly subjects (about ten hours) as compared to younger subjects (about seven hours). These changes were not of a magnitude that would be considered clinically relevant. </p>
<p><span class="Bold"><span class="Underline">Metformin hydrochloride </span></span></p>
<p>Limited data from controlled pharmacokinetic studies of metformin in healthy elderly subjects suggest that total CL/F is decreased, the t<span class="Sub">1/2 </span>is prolonged, and C<span class="Sub">max</span> is increased, compared to healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function. </p>
<p>As is true for all patients, pioglitazone and metformin hydrochloride tablets treatment should not be initiated in geriatric patients unless measurement of CL<span class="Sub">cr</span> demonstrates that renal function is not reduced [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_75c7c85e-1104-4b47-ac01-1d2707206413">5.2</a>)</span>]. </p>
<p><span class="Bold"><span class="Italics">Pediatrics </span></span></p>
<p><span class="Bold"><span class="Underline">Pioglitazone </span></span></p>
<p>Safety and efficacy of pioglitazone in pediatric patients have not been established. Pioglitazone and metformin hydrochloride tablets are not recommended for use in pediatric patients [<span class="Italics">see Use in Specific Populations (<a href="#i4i_pediatric_use_id_ed0239f2-e5ad-48a2-a3f6-8a3714154972">8.4</a>)</span>]. </p>
<p><span class="Bold"><span class="Underline">Metformin hydrochloride</span></span></p>
<p>After administration of a single oral metformin 500 mg tablet with food, geometric mean metformin C<span class="Sub">max</span> and AUC differed less than 5% between pediatric type 2 diabetic patients (12 to 16 years of age) and gender- and weight-matched healthy adults (20 to 45 years of age), and all with normal renal function. </p>
<p><span class="Bold"><span class="Italics">Gender </span></span></p>
<p><span class="Bold"><span class="Underline">Pioglitazone </span></span></p>
<p>The mean C<span class="Sub">max</span> and AUC values of pioglitazone were increased 20% to 60% in women compared to men. In controlled clinical trials, HbA1c decreases from baseline were generally greater for females than for males (average mean difference in HbA1c 0.5%). Because therapy should be individualized for each patient to achieve glycemic control, no dose adjustment is recommended based on gender alone.</p>
<p><span class="Bold"><span class="Underline">Metformin hydrochloride </span></span></p>
<p>Metformin pharmacokinetic parameters did not differ significantly between normal subjects and patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> when analyzed according to gender (males = 19, females = 16). Similarly, in controlled clinical studies in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, the antihyperglycemic effect of metformin was comparable in males and females. </p>
<p><span class="Bold"><span class="Italics">Ethnicity </span></span></p>
<p><span class="Bold"><span class="Underline">Pioglitazone </span></span></p>
<p>Pharmacokinetic data among various ethnic groups are not available. </p>
<p><span class="Bold"><span class="Underline">Metformin hydrochloride </span></span></p>
<p>No studies of metformin pharmacokinetic parameters according to race have been performed. In controlled clinical studies of metformin in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, the antihyperglycemic effect was comparable in whites (n = 249), blacks (n = 51), and Hispanics (n = 24). </p>
<p><span class="Bold">Drug-Drug Interactions</span></p>
<p>Specific pharmacokinetic drug interaction studies with pioglitazone and metformin hydrochloride tablets have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components.</p>
<p><span class="Bold"><span class="Italics">Pioglitazone</span></span></p>
<table width="100%">
<caption><span>Table 17: Effect of Pioglitazone Coadministration on Systemic Exposure of Other Drugs</span></caption>
<col width="21%">
<col width="41%">
<col width="12%">
<col width="7%">
<col width="12%">
<col width="7%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Daily for 7 days unless otherwise noted</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>% change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">‡</a></dt>
<dd>Pioglitazone had no clinically significant effect on <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="5"><p class="First"><span class="Bold">Coadministered Drug</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Pioglitazone Dosage Regimen (mg)</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Name and Dose Regimens</span></p></td>
<td class="Botrule Lrule" align="center" colspan="2"><p class="First"><span class="Bold">Change in AUC</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">Change in C<span class="Sub">max</span></span><a href="#footnote-5" class="Sup">†</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="3">
<p class="First">45 mg</p>
<p>(N = 12)</p>
</td>
<td class="Botrule Lrule Rrule" colspan="5"><p class="First"><span class="Bold">Warfarin</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">‡</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="2"><p class="First">Daily loading then maintenance doses based PT and INR values Quick's Value = 35 ± 5%</p></td>
<td class="Botrule Lrule"><p class="First">R-Warfarin</p></td>
<td class="Botrule Lrule"><p class="First">↓ 3%</p></td>
<td class="Botrule Lrule Rrule"><p class="First">R-Warfarin      </p></td>
<td class="Botrule Lrule Rrule"><p class="First">↓ 2%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">S-Warfarin      </p></td>
<td class="Botrule Lrule"><p class="First">↓ 1%</p></td>
<td class="Botrule Lrule Rrule"><p class="First">S-Warfarin      </p></td>
<td class="Botrule Lrule Rrule"><p class="First">↑ 1%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="2">
<p class="First">45 mg</p>
<p>(N = 12)</p>
</td>
<td class="Botrule Lrule Rrule" colspan="5"><p class="First"><span class="Bold">Digoxin</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">0.200 mg twice daily (loading dose) then 0.250 mg daily (maintenance dose, 7 days)</p></td>
<td class="Botrule Lrule" align="center" colspan="2"><p class="First">↑ 15%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First">↑ 17%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="3">
<p class="First">45 mg daily for 21 days</p>
<p>(N = 35)</p>
</td>
<td class="Botrule Lrule Rrule" colspan="5"><p class="First"><span class="Bold">Oral Contraceptive</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="2"><p class="First">[Ethinyl Estradiol (EE) 0.035 mg plus Norethindrone (NE) 1 mg] for 21 days</p></td>
<td class="Botrule Lrule" align="center"><p class="First">EE</p></td>
<td class="Botrule Lrule"><p class="First">↓ 11%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">EE                  </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">↓ 13%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">NE                   </p></td>
<td class="Botrule Lrule" align="center"><p class="First">↑ 3%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NE</p></td>
<td class="Botrule Lrule Rrule"><p class="First">↓ 7%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="2">
<p class="First">45 mg</p>
<p>(N = 23)</p>
</td>
<td class="Botrule Lrule Rrule" colspan="5"><p class="First"><span class="Bold">Fexofenadine</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">60 mg twice daily for 7 days</p></td>
<td class="Botrule Lrule" align="center" colspan="2"><p class="First">↑ 30%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First">↑ 37%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="2">
<p class="First">45 mg</p>
<p>(N = 14)</p>
</td>
<td class="Botrule Lrule Rrule" colspan="5"><p class="First"><span class="Bold">Glipizide</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">5 mg daily for 7 days </p></td>
<td class="Botrule Lrule" align="center" colspan="2"><p class="First">↓ 3%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First">↓ 8%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="2">
<p class="First">45 mg daily for 8 days</p>
<p>(N = 16)</p>
</td>
<td class="Botrule Lrule Rrule" colspan="5"><p class="First"><span class="Bold">Metformin</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">1000 mg single dose on Day 8 </p></td>
<td class="Botrule Lrule" align="center" colspan="2"><p class="First">↓ 3%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First">↓ 5%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="2">
<p class="First">45 mg</p>
<p>(N = 21)</p>
</td>
<td class="Botrule Lrule Rrule" colspan="5"><p class="First"><span class="Bold">Midazolam</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">7.5 mg single dose on Day 15 </p></td>
<td class="Botrule Lrule" align="center" colspan="2"><p class="First">↓ 26%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First">↓ 26%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="2">
<p class="First">45 mg</p>
<p>(N = 24)</p>
</td>
<td class="Botrule Lrule Rrule" colspan="5"><p class="First"><span class="Bold">Ranitidine</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">150 mg twice daily for 7 days </p></td>
<td class="Botrule Lrule" align="center" colspan="2"><p class="First">↑ 1%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First">↓ 1%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="2">
<p class="First">45 mg daily for 4 days</p>
<p>(N = 24)</p>
</td>
<td class="Botrule Lrule Rrule" colspan="5"><p class="First"><span class="Bold">Nifedipine ER</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">30 mg daily for 4 days </p></td>
<td class="Botrule Lrule" align="center" colspan="2"><p class="First">↓ 13%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First">↓ 17%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="2">
<p class="First">45 mg</p>
<p>(N = 25)</p>
</td>
<td class="Botrule Lrule Rrule" colspan="5"><p class="First"><span class="Bold">Atorvastatin Ca</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">80 mg daily for 7 days </p></td>
<td class="Botrule Lrule" align="center" colspan="2"><p class="First">↓ 14%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First">↓ 23%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="2">
<p class="First">45 mg</p>
<p>(N = 22)</p>
</td>
<td class="Botrule Lrule Rrule" colspan="5"><p class="First"><span class="Bold">Theophylline</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">400 mg twice daily for 7 days </p></td>
<td class="Botrule Lrule" align="center" colspan="2"><p class="First">↑ 2%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First">↑ 5%</p></td>
</tr>
</tbody>
</table>
<table width="100%">
<caption><span>Table 18: Effect of Coadministered Drugs on Pioglitazone Systemic Exposure</span></caption>
<col width="43%">
<col width="21%">
<col width="18%">
<col width="17%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Daily for 7 days unless otherwise noted</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>Mean ratio (with/without coadministered drug and no change = 1 fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">‡</a></dt>
<dd>The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_a213629f-661b-4969-9f42-971871d9844e">2.3</a>) and Drug Interactions (<a href="#i4i_section_id_d3254fd0-d618-417d-8d53-4556a0126bf8">7.1</a>)</span>]</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" rowspan="2"><p class="First"><span class="Bold">Coadministered Drug and Dosage Regimen</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Pioglitazone</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Dose Regimen (mg)</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Change in AUC</span><a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Change in C<span class="Sub">max</span></span><a href="#footnote-8" class="Sup">†</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">
<p class="First">Gemfibrozil 600 mg twice daily for 2 days </p>
<p>(N = 12)</p>
</td>
<td class="Botrule Lrule" align="center"><p class="First">15 mg single dose</p></td>
<td class="Botrule Lrule" align="center"><p class="First">↑3.2 fold<a name="footnote-reference-9" href="#footnote-9" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">↑6%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">
<p class="First">Ketoconazole 200 mg twice daily for 7 days </p>
<p>(N = 28)</p>
</td>
<td class="Botrule Lrule" align="center"><p class="First">45 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">↑34%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">↑14%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">
<p class="First">Rifampin 600 mg daily for 5 days </p>
<p>(N = 10)</p>
</td>
<td class="Botrule Lrule" align="center"><p class="First">30 mg single dose</p></td>
<td class="Botrule Lrule" align="center"><p class="First">↓54%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">↓5%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">
<p class="First">Fexofenadine 60 mg twice daily for 7 days </p>
<p>(N = 23)</p>
</td>
<td class="Botrule Lrule" align="center"><p class="First">45 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">↑1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">
<p class="First">Ranitidine 150 mg twice daily for 4 days </p>
<p>(N = 23)</p>
</td>
<td class="Botrule Lrule" align="center"><p class="First">45 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">↓13%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">↓16%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">
<p class="First">Nifedipine ER 30 mg daily for 7 days</p>
<p>(N = 23)</p>
</td>
<td class="Botrule Lrule" align="center"><p class="First">45 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">↑5%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">↑4%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">
<p class="First">Atorvastatin Ca 80 mg daily for 7 days</p>
<p>(N = 24)</p>
</td>
<td class="Botrule Lrule" align="center"><p class="First">45 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">↓24%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">↓31%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center">
<p class="First">Theophylline 400 mg twice daily for 7 days </p>
<p>(N = 22)</p>
</td>
<td class="Botrule Lrule" align="center"><p class="First">45 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">↓4%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">↓2%</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics">Metformin hydrochloride</span></p>
<table width="100%">
<caption><span>Table 19: Effect of Coadministered Drug on Plasma Metformin Systemic Exposure</span></caption>
<col width="16%">
<col width="16%">
<col width="12%">
<col width="29%">
<col width="28%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>All metformin and coadministered drugs were given as single doses</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">†</a></dt>
<dd>AUC = AUC<span class="Sub">0–∞</span>
</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">‡</a></dt>
<dd>Metformin hydrochloride extended-release tablets, 500 mg</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">§</a></dt>
<dd>Ratio of arithmetic means</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">¶</a></dt>
<dd>At steady-state with topiramate 100 mg every 12 hours and metformin 500 mg every 12 hours; AUC = AUC0-12h</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center" rowspan="2"><p class="First"><span class="Bold">Coadministered Drug</span></p></td>
<td class="Botrule Lrule Toprule" align="center" rowspan="2"><p class="First"><span class="Bold">Dose of Coadministered Drug</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a></p></td>
<td class="Botrule Lrule Toprule" align="center" rowspan="2"><p class="First"><span class="Bold">Dose of Metformin</span><a href="#footnote-10" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">
<p class="First"><span class="Bold">Geometric Mean Ratio (ratio with/without coadministered drug)</span></p>
<p><span class="Bold">No effect = 1.00</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">AUC</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">C<span class="Sub">max</span></span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5"><p class="First">No dosing adjustments required for the following:</p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First">Glyburide </p></td>
<td class="Botrule Lrule" align="center"><p class="First">5 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">500 mg<a name="footnote-reference-12" href="#footnote-12" class="Sup">‡</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">0.98<a name="footnote-reference-13" href="#footnote-13" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.99<a href="#footnote-13" class="Sup">§</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Furosemide </p></td>
<td class="Botrule Lrule" align="center"><p class="First">40 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">850 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1.09<a href="#footnote-13" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.22<a href="#footnote-13" class="Sup">§</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Nifedipine </p></td>
<td class="Botrule Lrule" align="center"><p class="First">10 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">850 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1.16</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.21</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Propranolol </p></td>
<td class="Botrule Lrule" align="center"><p class="First">40 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">850 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0.90</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.94</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Ibuprofen </p></td>
<td class="Botrule Lrule" align="center"><p class="First">400 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">850 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1.05<a href="#footnote-13" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.07<a href="#footnote-13" class="Sup">§</a></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5"><p class="First">Cationic drugs eliminated by renal tubular secretion may reduce metformin elimination: use with caution [<span class="Italics">see Warnings and Precautions (<a href="#i4i_warnings_precautions_id_6b3adf65-1552-4b86-b99a-a1c9cb4fb2d7">5</a>) and Drug Interactions (<a href="#i4i_interactions_id_e4fe1c67-dbc5-4b48-bb4c-baf5c9c146e8">7</a>)</span>].</p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First">Cimetidine </p></td>
<td class="Botrule Lrule" align="center"><p class="First">400 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">850 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1.40</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.61</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5"><p class="First">Carbonic anhydrase inhibitors may cause <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>: use with caution [<span class="Italics">see Warnings and Precautions (<a href="#i4i_warnings_precautions_id_6b3adf65-1552-4b86-b99a-a1c9cb4fb2d7">5</a>) and Drug Interactions (<a href="#i4i_interactions_id_e4fe1c67-dbc5-4b48-bb4c-baf5c9c146e8">7</a>)</span>].</p></td></tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Topiramate </p></td>
<td class="Botrule Lrule" align="center"><p class="First">100 mg<a name="footnote-reference-14" href="#footnote-14" class="Sup">¶</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">500 mg<a href="#footnote-14" class="Sup">¶</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">1.25<a href="#footnote-14" class="Sup">¶</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.17</p></td>
</tr>
</tbody>
</table>
<table width="100%">
<caption><span>Table 20: Effect of Metformin on Coadministered Drug Systemic Exposure</span></caption>
<col width="16%">
<col width="16%">
<col width="12%">
<col width="29%">
<col width="28%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">*</a></dt>
<dd>All metformin and coadministered drugs were given as single doses</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">†</a></dt>
<dd>AUC = AUC<span class="Sub">0–∞</span>
</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">‡</a></dt>
<dd>AUC<span class="Sub">0-24hr</span> reported</dd>
<dt><a name="footnote-18" href="#footnote-reference-18">§</a></dt>
<dd>Ratio of arithmetic means, p-value of difference &lt; 0.05</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">¶</a></dt>
<dd>Ratio of arithmetic means</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center" rowspan="2"><p class="First"><span class="Bold">Coadministered Drug</span></p></td>
<td class="Botrule Lrule Toprule" align="center" rowspan="2"><p class="First"><span class="Bold">Dose of Coadministered Drug</span><a name="footnote-reference-15" href="#footnote-15" class="Sup">*</a></p></td>
<td class="Botrule Lrule Toprule" align="center" rowspan="2"><p class="First"><span class="Bold">Dose of Metformin</span><a href="#footnote-15" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Geometric Mean Ratio (ratio with/without coadministered drug) No effect = 1.00</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">AUC</span><a name="footnote-reference-16" href="#footnote-16" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">C<span class="Sub">max</span></span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5"><p class="First">No dosing adjustments required for the following:</p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First">Glyburide </p></td>
<td class="Botrule Lrule" align="center"><p class="First">5 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">500 mg<a name="footnote-reference-17" href="#footnote-17" class="Sup">‡</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">0.78<a name="footnote-reference-18" href="#footnote-18" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.63<a href="#footnote-18" class="Sup">§</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Furosemide </p></td>
<td class="Botrule Lrule" align="center"><p class="First">40 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">850 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0.87<a href="#footnote-18" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.69<a href="#footnote-18" class="Sup">§</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Nifedipine </p></td>
<td class="Botrule Lrule" align="center"><p class="First">10 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">850 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1.10<a href="#footnote-17" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.08</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Propranolol </p></td>
<td class="Botrule Lrule" align="center"><p class="First">40 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">850 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1.01<a href="#footnote-17" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.94</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Ibuprofen </p></td>
<td class="Botrule Lrule" align="center"><p class="First">400 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">850 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0.97<a name="footnote-reference-19" href="#footnote-19" class="Sup">¶</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.01<a href="#footnote-19" class="Sup">¶</a></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Cimetidine </p></td>
<td class="Botrule Lrule" align="center"><p class="First">400 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">850 mg</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0.95<a href="#footnote-17" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.01</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_3232a6d2-0dd4-4365-91b6-fa6281b4aa65"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_83434e02-87f4-48d8-b22d-9553b9c8bd59"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Bold">Pioglitazone and metformin hydrochloride tablets </span></p>
<p>No animal studies have been conducted with pioglitazone and metformin hydrochloride tablets. The following data are based on findings in studies performed with pioglitazone or metformin individually. </p>
<p><span class="Bold">Pioglitazone </span></p>
<p>A two-year carcinogenicity study was conducted in male and female rats at oral doses up to 63 mg/kg (approximately 14 times the maximum recommended human oral dose of 45 mg based on mg/m<span class="Sup">2</span>). Drug-induced tumors were not observed in any organ except for the urinary bladder of male rats. Benign and/or malignant transitional cell neoplasms were observed in male rats at 4 mg/kg/day and above (approximately equal to the maximum recommended human oral dose based on mg/m<span class="Sup">2</span>). Urinary calculi with subsequent irritation and <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> were postulated as the mechanism for bladder tumors observed in male rats. A two-year mechanistic study in male rats utilizing dietary acidification to reduce calculi formation was completed in 2009. Dietary acidification decreased but did not abolish the hyperplastic changes in the bladder. The presence of calculi exacerbated the hyperplastic response to pioglitazone but was not considered the primary cause of the hyperplastic changes. </p>
<p>The relevance to humans of the bladder findings in the male rat cannot be excluded. </p>
<p>A two-year carcinogenicity study was also conducted in male and female mice at oral doses up to 100 mg/kg/day<br>(approximately 11 times the maximum recommended human oral dose based on mg/m<span class="Sup">2</span>). No drug-induced tumors were observed in any organ. </p>
<p>Pioglitazone hydrochloride was not mutagenic in a battery of genetic toxicology studies, including the Ames bacterial assay, a mammalian cell forward gene mutation assay (CHO/HPRT and AS52/XPRT), an <span class="Italics">in vitro </span>cytogenetics assay using CHL cells, an unscheduled DNA synthesis assay, and an <span class="Italics">in vivo </span>micronucleus assay.<br></p>
<p>No adverse effects upon fertility were observed in male and female rats at oral doses up to 40 mg/kg pioglitazone hydrochloride daily prior to and throughout mating and gestation (approximately nine times the maximum recommended human oral dose based on mg/m<span class="Sup">2</span>). </p>
<p><span class="Bold">Metformin hydrochloride </span></p>
<p>Long-term carcinogenicity studies have been performed in rats (dosing duration of 104 weeks) and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg/day and 1500 mg/kg/day, respectively. These doses are both approximately four times a human daily dose of 2000 mg of the metformin component of pioglitazone and metformin hydrochloride tablets based on body surface area comparisons. No evidence of carcinogenicity with metformin was found in either male or female mice. Similarly, there was no tumorigenic potential observed with metformin in male rats. There was, however, an increased incidence of benign stromal uterine <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> in female rats treated with 900 mg/kg/day. </p>
<p>There was no evidence of mutagenic potential of metformin in the following <span class="Italics">in vitro</span> tests: Ames test (S. <span class="Italics">typhimurium</span>), gene mutation test (mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells), or chromosomal aberrations test (human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>). Results in the<span class="Italics"> in vivo</span> mouse micronucleus test were also negative. </p>
<p>Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately three times the maximum recommended human daily dose of the metformin component of pioglitazone and metformin hydrochloride tablets based on body surface area comparisons. </p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_5a6e03ea-5ed0-4375-a2fd-be6b240e6ee6"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">Heart enlargement has been observed in mice (100 mg/kg), rats (4 mg/kg and above) and dogs (3 mg/kg) treated orally with pioglitazone hydrochloride (approximately 11, one, and two times the maximum recommended human oral dose for mice, rats, and dogs, respectively, based on mg/m<span class="Sup">2</span>). In a one-year rat study, drug-related early <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to apparent heart dysfunction occurred at an oral dose of 160 mg/kg/day (approximately 35 times the maximum recommended human oral dose based on mg/m<span class="Sup">2</span>). Heart enlargement was seen in a 13 week study in monkeys at oral doses of 8.9 mg/kg and above (approximately four times the maximum recommended human oral dose based on mg/m<span class="Sup">2</span>), but not in a 52 week study at oral doses up to 32 mg/kg (approximately 13 times the maximum recommended human oral dose based on mg/m<span class="Sup">2</span>). </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_4f919de5-f3dd-41b3-960f-3dda207644eb"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fc425785-64a7-4918-8688-41185652d5e7"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Patients Who Have Inadequate Glycemic Control with Diet and Exercise Alone</h2>
<p class="First">In a 24-week, randomized, double-blind clinical trial, 600 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus inadequately controlled with diet and exercise alone (mean baseline HbA1c 8.7%) were randomized to pioglitazone and metformin hydrochloride 15/850 mg, pioglitazone 15 mg, or metformin 850 mg twice daily. Statistically significant improvements in HbA1c and fasting plasma glucose (FPG) were observed in patients treated with pioglitazone and metformin hydrochloride tablets compared to either pioglitazone or metformin alone (see <a href="#_Ref413765040">Table 21</a>).</p>
<a name="_Ref413765040"></a><table width="100%">
<caption><span>Table 21: Glycemic Parameters in 24-Week Study of Pioglitazone and Metformin Hydrochloride Tablets in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus Inadequately Controlled with Diet and Exercise</span></caption>
<col width="39%">
<col width="21%">
<col width="18%">
<col width="16%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-20" href="#footnote-reference-20">*</a></dt>
<dd>Adjusted for baseline</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">†</a></dt>
<dd>p ≤ 0.05 versus pioglitazone and metformin hydrochloride tablets</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First Toprule">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Parameter </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="middle"><p class="First"><span class="Bold">Treatment Group </span></p></td>
</tr>
<tr class="Toprule">
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Pioglitazone and Metformin Hydrochloride Tablets</span></p>
<p><span class="Bold">15/850 mg</span></p>
<p><span class="Bold">Twice Daily</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Pioglitazone</span></p>
<p><span class="Bold">15 mg</span></p>
<p><span class="Bold">Twice Daily</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Metformin</span></p>
<p><span class="Bold">850 mg</span></p>
<p><span class="Bold">Twice Daily</span></p>
</td>
</tr>
<tr class="Toprule">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First"><span class="Bold">HbA1c (%) </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">N = 188 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">N = 162 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">N = 193 </p></td>
</tr>
<tr class="Toprule">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt> </dt>
<dd>Baseline (mean) </dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">8.9 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">8.7 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">8.7 </p></td>
</tr>
<tr class="Toprule">
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt> </dt>
<dd>Change from Baseline (adjusted mean<a name="footnote-reference-20" href="#footnote-20" class="Sup">*</a>) </dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">-1.8 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">-1.0 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">-1.0 </p></td>
</tr>
<tr class="Toprule">
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt> </dt>
<dd>Difference between</dd>
<dt> </dt>
<dd>pioglitazone and metformin hydrochloride tablets (adjusted mean<a href="#footnote-20" class="Sup">*</a>)</dd>
<dt> </dt>
<dd>95% Confidence Interval </dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">0.9<a name="footnote-reference-21" href="#footnote-21" class="Sup">†</a></p>
<p>(0.5, 1.2)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">0.8<a href="#footnote-21" class="Sup">†</a></p>
<p>(0.5, 1.2) </p>
</td>
</tr>
<tr class="Toprule">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt> </dt>
<dd>% of patients with HbA1c ≤ 7% </dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">64 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">47 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">39 </p></td>
</tr>
<tr class="Toprule">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First"><span class="Bold">Fasting Plasma Glucose (mg/dL) </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">N = 196 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">N = 176 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">N = 202 </p></td>
</tr>
<tr class="Toprule">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt> </dt>
<dd>Baseline (mean) </dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">177 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">171 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">171 </p></td>
</tr>
<tr class="Toprule">
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt> </dt>
<dd>Change from Baseline (adjusted mean<a href="#footnote-20" class="Sup">*</a>) </dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">-40 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">-22 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">-25 </p></td>
</tr>
<tr class="Last Toprule">
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt> </dt>
<dd>Difference between</dd>
<dt> </dt>
<dd>pioglitazone and metformin hydrochloride tablets (adjusted mean<a href="#footnote-20" class="Sup">*</a>)</dd>
<dt> </dt>
<dd>95% Confidence Interval </dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">18<a href="#footnote-21" class="Sup">†</a></p>
<p>(8, 28)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">15<a href="#footnote-21" class="Sup">†</a></p>
<p>(6, 25) </p>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5bd59774-77d3-40a7-bd85-23d257e716aa"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Patients Previously Treated With Metformin </h2>
<p class="First">The efficacy and safety of pioglitazone as add-on to metformin therapy have been established in two clinical studies. Bioequivalence of pioglitazone and metformin hydrochloride tablets with coadministered pioglitazone and metformin tablets was demonstrated for both pioglitazone and metformin hydrochloride tablets strengths [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_6b289b9c-e13b-4de0-9850-a6a18dc42bad">12.3</a>)</span>]. </p>
<p>The two clinical trials testing pioglitazone as add-on to metformin therapy included patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> on any dose of metformin, either alone or in combination with another antidiabetic agent. All other antidiabetic agents were withdrawn at least three weeks prior to starting study treatment. </p>
<p>In the first trial, 328 patients were randomized to receive either 30 mg of pioglitazone or placebo once daily for 16 weeks in addition to their current metformin regimen. Treatment with pioglitazone as add-on to metformin produced statistically significant improvements in HbA1c and FPG at endpoint compared to placebo add-on to metformin (see <a href="#_RefID503644E373A44AC69520C46526C40696">Table 22</a>).</p>
<table width="100%">
<caption><span>Table 22: Glycemic Parameters in a 16 Week Placebo-Controlled, Add-on to Metformin Trial</span></caption>
<col width="69%">
<col width="12%">
<col width="19%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-22" href="#footnote-reference-22">*</a></dt>
<dd>Adjusted for baseline, pooled center, and pooled center by treatment interaction</dd>
<dt><a name="footnote-23" href="#footnote-reference-23">†</a></dt>
<dd>p ≤ 0.05 vs. placebo + metformin</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold">Placebo </span></p>
<p><span class="Bold">+ </span></p>
<p><span class="Bold">Metformin</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Pioglitazone 30 mg </span></p>
<p><span class="Bold">+ </span></p>
<p><span class="Bold">Metformin</span></p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold">Total Population </span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">HbA1c (%)</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">N = 153</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">N = 161</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">9.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Change from baseline (adjusted mean<a name="footnote-reference-22" href="#footnote-22" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-0.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Difference from placebo + metformin (adjusted mean<a href="#footnote-22" class="Sup">*</a>) 95% Confidence Interval</p></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">-0.8<a name="footnote-reference-23" href="#footnote-23" class="Sup">†</a></p>
<p>(-1.2, -0.5)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Fasting Plasma Glucose (mg/dL) </span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">N = 157</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">N = 165</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Baseline (mean) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">260</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">254</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Change from baseline (adjusted mean<a href="#footnote-22" class="Sup">*</a>) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">-5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-43</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Difference from placebo + metformin (adjusted mean<a href="#footnote-2" class="Sup">*</a>) 95% Confidence Interval </p></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">-38<a href="#footnote-23" class="Sup">†</a></p>
<p>(-49, -26)</p>
</td>
</tr>
</tbody>
</table>
<p>In the second trial, 827 patients were randomized to receive either 30 mg or 45 mg of pioglitazone once daily for 24 weeks in addition to their current metformin regimen. The mean reduction from baseline at Week 24 in HbA1c was 0.8% for the 30 mg dose and 1.0% for the 45 mg dose (see <a href="#_RefID124EE68A115F48928018636E21CABA21">Table 23</a>). The mean reduction from baseline at Week 24 in FPG was 38 mg/dL for the 30 mg dose and 51 mg/dL for the 45 mg dose.</p>
<table width="100%">
<caption><span>Table 23: Glycemic Parameters in a 24 Week Add-on to Metformin Study</span></caption>
<col width="51%">
<col width="24%">
<col width="24%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-24" href="#footnote-reference-24">*</a></dt>
<dd>Adjusted for baseline, pooled center, and pooled center by treatment interaction</dd>
<dt><a name="footnote-25" href="#footnote-reference-25">†</a></dt>
<dd>p ≤ 0.05 vs. 30 mg daily pioglitazone + metformin</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Pioglitazone 30 mg + Metformin</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Pioglitazone 45 mg + Metformin</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold">Total Population</span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">HbA1c (%) </span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">N = 400</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">N = 398</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Baseline (mean) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">9.9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Change from baseline (adjusted mean<a name="footnote-reference-24" href="#footnote-24" class="Sup">*</a>) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">-0.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-1.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Difference from 30 mg daily pioglitazone + metformin (adjusted mean<a href="#footnote-24" class="Sup">*</a>) (95% CI) </p></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">-0.2</p>
<p>(-0.5, 0.1)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Fasting Plasma Glucose (mg/dL) </span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">N = 398</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">N = 399</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Baseline (mean) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">233</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">232</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Change from baseline (adjusted mean<a href="#footnote-24" class="Sup">*</a>) </p></td>
<td class="Botrule Lrule" align="center"><p class="First">-38</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-51</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Difference from 30 mg daily pioglitazone + metformin (adjusted mean<a href="#footnote-24" class="Sup">*</a>) (95% CI) </p></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">-12<a name="footnote-reference-25" href="#footnote-25" class="Sup">†</a></p>
<p>(-21, -4)</p>
</td>
</tr>
</tbody>
</table>
<p>The therapeutic effect of pioglitazone in combination with metformin was observed in patients regardless of the metformin dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_274d231e-0e86-4aa9-9290-89a29849ff80"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Pioglitazone and metformin hydrochloride tablets USP are available in 15 mg pioglitazone hydrochloride (as the base)/500 mg metformin hydrochloride and 15 mg pioglitazone hydrochloride (as the base)/850 mg metformin hydrochloride tablets as follows:</p>
<p>15 mg (base) and 500 mg: white to off-white, oval-shaped tablet, film-coated, debossed with “TV? on one side of the tablet and “7677? on the other side, in bottles of 60 (NDC 0093-7677-06) and 180 (NDC 0093-7677-86).</p>
<p>15 mg (base) and 850 mg: white to off-white, oval-shaped tablet, film-coated, debossed with “TV? on one side of the tablet and “7678? on the other side, in bottles of 60 (NDC 0093-7678-06) and 180 (NDC 0093-7678-86).</p>
<p><span class="Bold">Storage</span></p>
<p>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Keep container tightly closed, and protect from moisture and humidity.</p>
<p>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_6b956ca9-18ef-4a58-88da-4f20dd2fce54"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-Approved Patient Labeling (Medication Guide) </p>
<dl>
<dt>•</dt>
<dd>It is important to instruct patients to adhere to dietary instructions and to have blood glucose and <span class="product-label-link" type="condition" conceptid="4123836" conceptname="Glycosylated hemoglobin">glycosylated hemoglobin</span> tested regularly. During periods of stress such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or surgery, medication requirements may change and patients should be reminded to seek medical advice promptly. </dd>
<dt>•</dt>
<dd>Tell patients to promptly report any sign of <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">macroscopic hematuria</span> or other symptoms such as <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span> or <span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">urinary urgency</span> that develop or increase during treatment as these may be due to <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>. </dd>
<dt>•</dt>
<dd>Explain to patients the risks of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, its symptoms and conditions that predispose to its development, as noted in the <span class="Italics">Warnings and Precautions (<a href="#i4i_section_id_75c7c85e-1104-4b47-ac01-1d2707206413">5.2</a>)</span> section. Advise patients to discontinue pioglitazone and metformin hydrochloride tablets immediately and to promptly notify their healthcare professional if unexplained <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, unusual <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, or other nonspecific symptoms occur. </dd>
<dt>•</dt>
<dd>Counsel patients against excessive alcohol intake while receiving pioglitazone and metformin hydrochloride tablets.</dd>
<dt>•</dt>
<dd>Inform patients to immediately report symptoms of an unusually rapid increase in weight or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, or other symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> while receiving pioglitazone and metformin hydrochloride tablets. </dd>
<dt>•</dt>
<dd>Tell patients to promptly stop taking pioglitazone and metformin hydrochloride tablets and seek immediate medical advice if there is unexplained <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, or dark urine as these symptoms may be due to hepatotoxicity. </dd>
<dt>•</dt>
<dd>Inform patients about the importance of regular testing of renal function and hematologic parameters when receiving treatment with pioglitazone and metformin hydrochloride tablets. </dd>
<dt>•</dt>
<dd>Inform patients that therapy with a thiazolidinedione, which is the active pioglitazone component of the pioglitazone and metformin hydrochloride tablets, may result in ovulation in some premenopausal anovulatory women. As a result, these patients may be at an increased risk for pregnancy while taking pioglitazone and metformin hydrochloride tablets. Recommend adequate contraception for all premenopausal women who are prescribed pioglitazone and metformin hydrochloride tablets. </dd>
<dt>•</dt>
<dd>Patients should be advised to notify their health practitioner or call the Poison Control Center immediately in case of pioglitazone and metformin hydrochloride tablets <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. </dd>
<dt>•</dt>
<dd>Combination antihyperglycemic therapy may cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. When initiating pioglitazone and metformin hydrochloride tablets, the risks of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and their family members. </dd>
<dt>•</dt>
<dd>Patients should be told to take pioglitazone and metformin hydrochloride tablets as prescribed and instructed that any change in dosing should only be done if directed by their physician. If a dose is missed on one day, the dose should not be doubled the following day.</dd>
</dl>
<p>Manufactured In Israel By:<br><span class="Bold">TEVA PHARMACEUTICAL IND. LTD.</span><br>Jerusalem, 9777402, Israel<br>Manufactured For:<br><span class="Bold">TEVA PHARMACEUTICALS USA, INC.</span><br>North Wales, PA 19454</p>
<p>Rev. C 5/2015</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="i4i_medguide_id_187dee00-d0d3-4933-bf49-a9abf4dd55b6"></a><a name="section-16"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">Pioglitazone (pie-oh-GLIT-ah-zohn) and Metformin (met-FORE-min) Hydrochloride Tablets USP </span></p>
<p>Read this Medication Guide carefully before you start taking pioglitazone and metformin hydrochloride tablets and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. If you have any questions about pioglitazone and metformin hydrochloride tablets, ask your doctor or pharmacist. </p>
<p><span class="Bold">What is the most important information I should know about pioglitazone and metformin hydrochloride tablets? </span></p>
<p><span class="Bold">Pioglitazone and metformin hydrochloride tablets can cause serious side effects, including: </span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">New or worse <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</span> Pioglitazone, one of the medicines in pioglitazone and metformin hydrochloride tablets, can cause your body to keep extra fluid (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>), which leads to <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>) and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. Extra body fluid can make some heart problems worse or lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span> means your heart does not pump blood well enough. <dl>
<dt>o</dt>
<dd>Do not take pioglitazone and metformin hydrochloride tablets if you have severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> </dd>
<dt>o</dt>
<dd>If you have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with symptoms (such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>), even if these symptoms are not severe, pioglitazone and metformin hydrochloride tablets may not be right for you. </dd>
</dl>
</dd>
<dt> </dt>
<dd>
<span class="Bold">Call your doctor right away if you have any of the following: </span><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, especially in the ankles or legs </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing, especially when you lie down </dd>
<dt>o</dt>
<dd>an unusually fast increase in weight </dd>
<dt>o</dt>
<dd>unusual <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> </dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>.</span> Metformin, one of the medicines in pioglitazone and metformin hydrochloride tablets, can cause a rare but serious condition called <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> (a buildup of an acid in the blood) that can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a medical emergency and must be treated in the hospital. </dd>
<dt> </dt>
<dd>
<span class="Bold">Call your doctor right away if you have any of the following symptoms, which could be signs of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>: </span><dl>
<dt>o</dt>
<dd>you feel weak or tired </dd>
<dt>o</dt>
<dd>you have unusual (not normal) <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> </dd>
<dt>o</dt>
<dd>you have <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pains</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </dd>
<dt>o</dt>
<dd>you have trouble breathing </dd>
<dt>o</dt>
<dd>you feel dizzy or lightheaded </dd>
<dt>o</dt>
<dd>you have a slow or irregular heartbeat </dd>
</dl>
</dd>
</dl>
<p>Most people who have had <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> with metformin have other things that, combined with the metformin, led to the <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. Tell your doctor if you have any of the following, because you have a higher chance for getting <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> with pioglitazone and metformin hydrochloride tablets if you: </p>
<dl>
<dt>•</dt>
<dd>have kidney problems or your kidneys are affected by certain x-ray tests that use injectable dye. People whose kidneys are not working properly should not take pioglitazone and metformin hydrochloride tablets </dd>
<dt>•</dt>
<dd>have liver problems </dd>
<dt>•</dt>
<dd>drink alcohol very often, or drink a lot of alcohol in short-term "binge" drinking</dd>
<dt>•</dt>
<dd>get dehydrated (lose a large amount of body fluids). This can happen if you are sick with a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span> can also happen when you sweat a lot with activity or exercise and do not drink enough fluids </dd>
<dt>•</dt>
<dd>have surgery </dd>
<dt>•</dt>
<dd>have a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> </dd>
<dt>•</dt>
<dd>are 80 years of age or older and have not had your kidneys tested </dd>
</dl>
<p>The best way to keep from having a problem with <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> from metformin is to tell your doctor if you have any of the problems in the list above. Your doctor may decide to stop your pioglitazone and metformin hydrochloride tablets for a while if you have any of these things. </p>
<p>Pioglitazone and metformin hydrochloride tablets can have other serious side effects. See “<span class="Bold">What are the possible side effects of pioglitazone and metformin hydrochloride tablets?</span>? </p>
<p><span class="Bold">What are pioglitazone and metformin hydrochloride tablets? </span></p>
<p>Pioglitazone and metformin hydrochloride tablets contain two prescription <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines called pioglitazone hydrochloride (ACTOS<span class="Sup">®</span>) and metformin hydrochloride (GLUCOPHAGE<span class="Sup">®</span>). Pioglitazone and metformin hydrochloride tablets can be used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. </p>
<p>Pioglitazone and metformin hydrochloride tablets are not for people with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. </p>
<p>Pioglitazone and metformin hydrochloride tablets are not for people with <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> (increased <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span> in your blood or urine). </p>
<p>It is not known if pioglitazone and metformin hydrochloride tablets are safe and effective in children under the age of 18. Pioglitazone and metformin hydrochloride tablets are not recommended for use in children.  </p>
<p><span class="Bold">Who should not take pioglitazone and metformin hydrochloride tablets? </span></p>
<p>See<span class="Bold"> “What is the most important information I should know about pioglitazone and metformin hydrochloride tablets??</span></p>
<p><span class="Bold">Do not take pioglitazone and metformin hydrochloride tablets if you: </span></p>
<dl>
<dt>•</dt>
<dd>have severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> </dd>
<dt>•</dt>
<dd>are allergic to pioglitazone, metformin, or any of the ingredients in pioglitazone and metformin hydrochloride tablets. See the end of this Medication Guide for a complete list of ingredients in pioglitazone and metformin hydrochloride tablets</dd>
<dt>•</dt>
<dd>have kidneys which are not working properly </dd>
<dt>•</dt>
<dd>have a condition called <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, including <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>. <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">Diabetic ketoacidosis</span> should be treated with insulin </dd>
</dl>
<p>Tell your doctor before taking pioglitazone and metformin hydrochloride tablets if you have any of these conditions. </p>
<p><span class="Bold">What should I tell my doctor before taking pioglitazone and metformin hydrochloride tablets? </span></p>
<p>Before you take pioglitazone and metformin hydrochloride tablets, tell your doctor if you: </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> </span></dd>
<dt>•</dt>
<dd><span class="Bold">have kidney problems </span></dd>
<dt>•</dt>
<dd><span class="Bold">are going to have dye injected into a vein for an x-ray, CAT scan, heart study, or other type of scanning </span></dd>
<dt>•</dt>
<dd><span class="Bold">will be undergoing a surgical procedure </span></dd>
<dt>•</dt>
<dd>
<span class="Bold">drink a lot of alcohol </span>(all the time or short binge drinking)</dd>
<dt>•</dt>
<dd><span class="Bold">have type 1 (“juvenile?) <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or had <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> </span></dd>
<dt>•</dt>
<dd><span class="Bold">have a type of diabetic eye disease that causes <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in the back of the eye (<span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span>) </span></dd>
<dt>•</dt>
<dd><span class="Bold">have liver problems</span></dd>
<dt>•</dt>
<dd><span class="Bold">have or have had cancer of the bladder</span></dd>
<dt>•</dt>
<dd>
<span class="Bold">are pregnant or plan to become pregnant.</span> It is not known if pioglitazone and metformin hydrochloride tablets will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant about the best way to control your blood glucose levels while pregnant </dd>
<dt>•</dt>
<dd>
<span class="Bold">are a premenopausal woman (before the “change of life?) who does not have periods regularly or at all.</span> Pioglitazone and metformin hydrochloride tablets may increase your chance of becoming pregnant. Talk to your doctor about birth control choices while taking pioglitazone and metformin hydrochloride tablets. Tell your doctor right away if you become pregnant while taking pioglitazone and metformin hydrochloride tablets </dd>
<dt>•</dt>
<dd>
<span class="Bold">are breastfeeding or plan to breastfeed.</span> It is not known if pioglitazone hydrochloride and metformin hydrochloride passes into your breast milk. You and your doctor should decide if you will take pioglitazone and metformin hydrochloride tablets or breastfeed. You should not do both. Talk to your doctor about the best way to control your blood glucose levels while breastfeeding </dd>
</dl>
<p><span class="Bold">Tell your doctor about all the medicines you take,</span> including prescription and over the counter medicines, vitamins, and herbal supplements. </p>
<p>Pioglitazone and metformin hydrochloride tablets and some of your other medicines can affect each other. You may need to have your dose of pioglitazone and metformin hydrochloride tablets or certain other medicines changed. </p>
<p>Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist before you start a new medicine. They will tell you if it is okay to take pioglitazone and metformin hydrochloride tablets with other medicines. </p>
<p><span class="Bold">How should I take pioglitazone and metformin hydrochloride tablets? </span></p>
<dl>
<dt>•</dt>
<dd>Take pioglitazone and metformin hydrochloride tablets exactly as your doctor tells you to take it</dd>
<dt>•</dt>
<dd>Your doctor may need to change your dose of pioglitazone and metformin hydrochloride tablets. Do not change your pioglitazone and metformin hydrochloride tablets dose unless your doctor tells you to </dd>
<dt>•</dt>
<dd>Pioglitazone and metformin hydrochloride tablets may be prescribed alone or with other <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines. This will depend on how well your blood sugar is controlled </dd>
<dt>•</dt>
<dd>Take pioglitazone and metformin hydrochloride tablets with meals to lower your chance of an <span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span> </dd>
<dt>•</dt>
<dd>If you miss a dose of pioglitazone and metformin hydrochloride tablets, take your next dose as prescribed unless your doctor tells you differently. <span class="Bold">Do not take</span> two doses at one time the next day </dd>
<dt>•</dt>
<dd>If you take too many pioglitazone and metformin hydrochloride tablets, call your doctor or go to the nearest hospital emergency room right away </dd>
<dt>•</dt>
<dd>If your body is under stress such as from a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>, or surgery, the dose of your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines may need to be changed. Call your doctor right away </dd>
<dt>•</dt>
<dd>Stay on your diet and exercise programs and test your blood sugar regularly while taking pioglitazone and metformin hydrochloride tablets </dd>
<dt>•</dt>
<dd>Your doctor should do certain blood tests before you start and while you take pioglitazone and metformin hydrochloride tablets </dd>
<dt>•</dt>
<dd>Your doctor should also do hemoglobin A1C testing to check how well your blood sugar is controlled with pioglitazone and metformin hydrochloride tablets </dd>
<dt>•</dt>
<dd>Your doctor should check your eyes regularly while you take pioglitazone and metformin hydrochloride tablets </dd>
</dl>
<p><span class="Bold">What are the possible side effects of pioglitazone and metformin hydrochloride tablets? </span></p>
<p><span class="Bold">Pioglitazone and metformin hydrochloride tablets may cause serious side effects, including: </span></p>
<dl>
<dt>•</dt>
<dd><span class="Bold">See “What is the most important information I should know about pioglitazone and metformin hydrochloride tablets??</span></dd>
<dt>•</dt>
<dd>
<span class="Bold">low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>).</span> This can happen if you skip meals, if you also use another medicine that lowers blood sugar, or if you have certain medical problems. <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shakiness</span>, or <span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span> may happen if your blood sugar is too low. Call your doctor if low blood sugar levels are a problem for you </dd>
<dt>•</dt>
<dd>
<span class="Bold">liver problems.</span> Call your doctor right away if you have: <dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> </dd>
<dt>o</dt>
<dd>unusual or unexplained <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> </dd>
<dt>o</dt>
<dd>loss of appetite </dd>
<dt>o</dt>
<dd>dark urine </dd>
<dt>o</dt>
<dd>yellowing of your skin or the whites of your eyes </dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>.</span> There may be an increased chance of having <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> when you take pioglitazone and metformin hydrochloride tablets. You should not take pioglitazone and metformin hydrochloride tablets if you are receiving treatment for <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>. Tell your doctor right away if you have any of the following symptoms of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>: <dl>
<dt>o</dt>
<dd>blood or a red color in your urine </dd>
<dt>o</dt>
<dd>an increased need to urinate </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> while you urinate </dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">broken bones (<span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>).</span> Usually in the hand, upper arm, or foot in women. Talk to your doctor for advice on how to keep your bones healthy </dd>
<dt>•</dt>
<dd>
<span class="Bold">diabetic eye disease with <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in the back of the eye (<span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span>).</span> Tell your doctor right away if you have any changes in your vision. Your doctor should check your eyes regularly</dd>
<dt>•</dt>
<dd>
<span class="Bold">release of an egg from an ovary in a woman (ovulation) leading to pregnancy. </span>Ovulation may happen when premenopausal women who do not have regular monthly periods take pioglitazone and metformin hydrochloride tablets. This can increase your chance of getting pregnant. </dd>
<dt>•</dt>
<dd><span class="Bold">low red blood cell count (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>). </span></dd>
</dl>
<p>The most common side effects of pioglitazone and metformin hydrochloride tablets include: </p>
<dl>
<dt> </dt>
<dd><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>-like symptoms (<span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>) </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>) </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> </dd>
<dt>o</dt>
<dd>increased weight </dd>
</dl></dd>
</dl>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the side effects of pioglitazone and metformin hydrochloride tablets. For more information, ask your doctor or pharmacist. </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
<p><span class="Bold">How should I store pioglitazone and metformin hydrochloride tablets? </span></p>
<dl>
<dt>•</dt>
<dd>Store pioglitazone and metformin hydrochloride tablets at 68° to 77°F (20° to 25°C). Keep pioglitazone and metformin hydrochloride tablets in their original container and protect from light</dd>
</dl>
<p>Keep the pioglitazone and metformin hydrochloride tablets bottle tightly closed keep tablets dry</p>
<p><span class="Bold">Keep pioglitazone and metformin hydrochloride tablets and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of pioglitazone and metformin hydrochloride tablets </span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use pioglitazone and metformin hydrochloride tablets for a condition for which they were not prescribed. Do not give pioglitazone and metformin hydrochloride tablets to other people, even if they have the same symptoms you have. They may harm them. </p>
<p>This Medication Guide summarizes the most important information about pioglitazone and metformin hydrochloride tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about pioglitazone and metformin hydrochloride tablets that is written for healthcare professionals. </p>
<p>For more information, call 1-888-838-2872.</p>
<p><span class="Bold">What are the ingredients in pioglitazone and metformin hydrochloride tablets USP? </span></p>
<p><span class="Bold">Active Ingredients</span>: pioglitazone hydrochloride, USP and metformin hydrochloride, USP </p>
<p><span class="Bold">Inactive Ingredients</span>: colloidal silicon dioxide, cornstarch, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, povidone, talc, and titanium dioxide</p>
<p>All brand names listed are the registered trademarks of their respective owners and are not trademarks of Teva Pharmaceuticals USA, INC.</p>
<p><span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
<p>Manufactured In Israel By:<br><span class="Bold">TEVA PHARMACEUTICAL IND. LTD.</span><br>Jerusalem, 9777402, Israel<br>Manufactured For:<br><span class="Bold">TEVA PHARMACEUTICALS USA, INC.</span><br>North Wales, PA 19454</p>
<p>Rev. B 8/2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_d1df33d6-a849-4f7b-be44-2a722896df18"></a><a name="section-17"></a><p></p>
<h1>Package/Label Display Panel</h1>
<div class="Figure">
<a name="id133072578"></a><img alt="Pioglitazone and Metformin Hydrochloride Tablets USP 15 mg/500 mg 60s Label " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7dbc36d-3c84-488e-9b72-0593b5ed53a0&amp;name=image-03.jpg">
</div>
<p class="First"><span class="Bold">Pioglitazone and Metformin Hydrochloride Tablets USP 15 mg/500 mg 60s Label Text</span></p>
<p><span class="Bold">NDC </span>0093<span class="Bold">-7677-</span>06</p>
<p><span class="Bold">PIOGLITAZONE and</span><br><span class="Bold">METFORMIN</span></p>
<p><span class="Bold">HYDROCHLORIDE</span></p>
<p><span class="Bold">Tablets USP</span><br><span class="Bold">15 mg/500 mg</span></p>
<p>PHARMACIST: Dispense the</p>
<p>accompanying Medication Guide </p>
<p>to each patient.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">60 TABLETS</span></p>
<p><span class="Bold">TEVA</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_b91d845b-61f4-4018-960b-b374b5748cff"></a><a name="section-18"></a><p></p>
<h1>Package/Label Display Panel</h1>
<div class="Figure">
<a name="id133072988"></a><img alt="Pioglitazone and Metformin Hydrochloride Tablets USP 15 mg/850 mg 60s Label " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7dbc36d-3c84-488e-9b72-0593b5ed53a0&amp;name=image-04.jpg">
</div>
<p class="First"><span class="Bold">Pioglitazone and Metformin Hydrochloride Tablets USP 15 mg/850 mg 60s Label Text </span></p>
<p><span class="Bold">NDC </span>0093<span class="Bold">-7678-</span>06</p>
<p><span class="Bold">PIOGLITAZONE and</span><br><span class="Bold">METFORMIN</span></p>
<p><span class="Bold">HYDROCHLORIDE</span></p>
<p><span class="Bold">Tablets USP</span><br><span class="Bold">15 mg/850 mg</span></p>
<p>PHARMACIST: Dispense the</p>
<p>accompanying Medication Guide </p>
<p>to each patient.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">60 TABLETS</span></p>
<p><span class="Bold">TEVA</span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PIOGLITAZONE AND METFORMIN HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">pioglitazone and metformin hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0093-7677</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PIOGLITAZONE HYDROCHLORIDE</strong> (PIOGLITAZONE) </td>
<td class="formItem">PIOGLITAZONE</td>
<td class="formItem">15 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>METFORMIN HYDROCHLORIDE</strong> (METFORMIN) </td>
<td class="formItem">METFORMIN HYDROCHLORIDE</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3350</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 4000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE K25</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K90</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TV;7677</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0093-7677-06</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">04/24/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0093-7677-86</td>
<td class="formItem">180  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">03/05/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091155</td>
<td class="formItem">03/05/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PIOGLITAZONE AND METFORMIN HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">pioglitazone and metformin hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0093-7678</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PIOGLITAZONE HYDROCHLORIDE</strong> (PIOGLITAZONE) </td>
<td class="formItem">PIOGLITAZONE</td>
<td class="formItem">15 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>METFORMIN HYDROCHLORIDE</strong> (METFORMIN) </td>
<td class="formItem">METFORMIN HYDROCHLORIDE</td>
<td class="formItem">850 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3350</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 4000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE K25</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K90</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TV;7678</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0093-7678-06</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">03/11/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0093-7678-86</td>
<td class="formItem">180  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">02/04/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091155</td>
<td class="formItem">02/04/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Teva Pharmaceuticals USA Inc
							(001627975)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>085ad17f-03eb-4d69-bc76-275b58f3f6b4</div>
<div>Set id: c7dbc36d-3c84-488e-9b72-0593b5ed53a0</div>
<div>Version: 4</div>
<div>Effective Time: 20150611</div>
</div>
</div> <div class="DistributorName">Teva Pharmaceuticals USA Inc</div></p>
</body></html>
